Application of epigenetic chromosomal interactions in cancer diagnosis

The MIQE-compliant chromosome conformation capture assay effectively identifies chromosomal interactions for personalized cancer treatment by quantifying specific interactions using dual-labeled probes, addressing the limitations of current diagnostic methods.

JP7579003B2Active Publication Date: 2024-11-07OXFORD BIODYNAMICS PLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022183117
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-01
Filing Date
2022-11-16
Publication Date
2024-11-07
Estimated Expiration
2037-11-30

AI Technical Summary

Technical Problem

Current cancer diagnostic methods are ineffective in capturing chromosomal interactions associated with responsiveness to tyrosine kinase inhibitor therapy, leading to potential misdiagnosis and inappropriate treatment.

Method used

A method for determining epigenetic chromosomal interactions using a MIQE-compliant chromosome conformation capture assay, which involves hybridizing complementary nucleic acid sequences and detecting ligated products with dual-labeled fluorescent hydrolysis probes to quantify specific chromosomal interactions.

Benefits of technology

This method allows for accurate identification of chromosomal interactions relevant to cancer prognosis and responsiveness to tyrosine kinase inhibitor therapy, enabling personalized treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579003000020
    Figure 0007579003000020
  • Figure 0007579003000021
    Figure 0007579003000021
  • Figure 0007579003000022
    Figure 0007579003000022
Patent Text Reader

Abstract

Methods for determining epigenetic chromosomal interactions associated with cancer prognosis companion epigenetic tests are provided. [Solution] A method is disclosed that includes contacting a first set of nucleic acids from the subgroup with a second set of nucleic acids representing an index population of chromosomal interactions and hybridizing complementary sequences, wherein the nucleic acids in the first and second sets of nucleic acids together represent a ligated product containing sequences from both chromosomal regions that epigenetic chromosomally interact, and determining which epigenetic chromosomal interactions are specific to a subgroup in the population based on the pattern of hybridization between the first and second sets of nucleic acids.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to chromosomal interactions. [Background technology]

[0002] The world's growing population expects fast and efficient service in all aspects of technology, especially in the field of medicine. Improvements in personalized therapy often rely on the use of biomarkers such as protein, mRNA, antibody and SNP markers. Summary of the Invention [Problem to be solved by the invention]

[0003] The present inventors have investigated the role of chromosomal interactions in cancer prognosis. Their research shows that specific chromosomal interactions are associated with specific outcomes, such as response to therapy. As part of this research, the present inventors have also developed a new epigenetic testing assay that is particularly suitable for detecting ligated nucleic acids that are generated during the process of detecting chromosomal interactions.

[0004] Thus, the present invention provides a method for determining epigenetic chromosomal interactions associated with a cancer prognosis companion epigenetic test that distinguishes between subgroups, comprising contacting a first set of nucleic acids from the subgroup with a second set of nucleic acids representative of an index population of chromosomal interactions and hybridizing complementary sequences, where the nucleic acids in the first and second sets of nucleic acids represent ligated products that together contain sequences from both chromosomal regions that epigenetically interact, and the pattern of hybridization between the first and second sets of nucleic acids allows for the determination of which epigenetic chromosomal interactions are specific to the subgroups in the population, where the subgroups differ in at least one characteristic associated with prognosis. Typically, the subgroups differ with respect to responsiveness to tyrosine kinase inhibitor therapy, and / or the cancer is associated with aberrant expression from kinase genes and / or tyrosine kinase receptor genes, and / or the cancer is associated with genetic or epigenetic changes in one or more of the following genes: FIP1L1, PDGFRA, Flt3, ABL1, FGFR1 and cKIT.

[0005] The present invention also provides a method for determining cancer prognosis comprising: (a) classifying the chromosomal interactions identified by said method, and / or (b) detecting (i) responsiveness to tyrosine kinase inhibitor therapy, and / or (ii) aberrant expression from kinase genes and / or tyrosine kinase receptor genes, and / or (iii) the presence or absence of at least one epigenetic chromosomal interaction associated with one or more of the following genes: FIP1L1, PDGFRA, Flt3, ABL1, FGFR1 and cKIT.

[0006] The present invention further provides a method for quantitatively detecting ligated sequences associated with chromosomal interactions using a probe that is detectable upon activation during a PCR reaction, the ligated sequences comprising sequences from two chromosomal regions that together form an epigenetic chromosomal interaction, the method comprising contacting the ligated sequences with a probe during a PCR reaction and detecting the degree of activation of the probe, the probe binding to the ligation site. This method allows the detection of specific interactions in a MIQE-compliant manner using dual-labeled fluorescent hydrolysis probes.

[0007] Applicants' work provides industry with the first MIQE-compliant chromosome conformation (3C) assay for determining prognosis in oncological settings. [Brief description of the drawings]

[0008] [Figure 1] Figure 1 is a schematic diagram of the 3C process. 3C stands for chromatin conformation capture, or chromosome conformation capture. [Diagram 2] Figure 2 is a graph of curvature and bendability versus sequence position for ligated sequence 1. Expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-9 on the left Y-axis) and bendability in au is shown in grey (scale 4-6.5 on the right Y-axis). Sequence number in base pairs from 0 to 500 is shown on the X-axis. [Diagram 3] Figure 3 is a graph of curvature and bendability versus sequence position for ligated sequence 2. Expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-12 on the left Y-axis) and bendability in au is shown in grey (scale 3-6.5 on the right Y-axis). Sequence number in base pairs from 0 to 700 is shown on the X-axis. [Figure 4]Figure 4 is a graph of curvature and bendability versus sequence position for ligated sequence 3. Expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-9 on the left Y-axis) and bendability in au is shown in grey (scale 4-6 on the right Y-axis). Sequence number in base pairs from 0 to 450 is shown on the X-axis. [Diagram 5] Figure 5 is a graph of curvature and bendability versus sequence position for the ligated sequence 4. The expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-10 on the left Y-axis) and bendability in au in grey (scale 3-7 on the right Y-axis). The sequence number in base pairs from 0 to 500 is shown on the X-axis. [Figure 6] Figure 6 is a graph of curvature and bendability versus sequence position for ligated sequence 5. Expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-9 on the left Y-axis) and bendability in au is shown in grey (scale 3-6.5 on the right Y-axis). Sequence number in base pairs from 0 to 700 is shown on the X-axis. [Figure 7] Figure 7 is a graph of curvature and bendability versus sequence position for ligated sequence 6. Expected curvature in degrees per 10.5 bp helical turn is shown in black (scale 0-12 on the left Y-axis) and bendability in au is shown in grey (scale 3-6.5 on the right Y-axis). Sequence number in base pairs from 0 to 600 is shown on the X-axis. [Figure 8] FIG. 8 shows data relating to treatment embodiments. [Figure 9] FIG. 9 shows data relating to treatment embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention is particularly directed to identifying certain abnormal processes using robust quantitative tests. The present invention has several different aspects, including, inter alia: Methods for identifying epigenetic chromosomal interactions associated with different subgroups Methods for identifying subgroups of individuals Method for quantitatively detecting ligated sequences associated with chromosomal interactions a hydrolysis probe that is detectable upon activation during a PCR reaction and that binds to the ligation site of the ligated nucleic acid; How to Select Primers and Probes for Use in PCR Reactions How to Treat Cancer Nucleic Acids for Use in Cancer Treatment How to identify therapeutic drugs.

[0010] Cancers related to the present invention The present invention relates to epigenetic interactions associated with cancer, for example cancer caused by different genetic mechanisms, such as mutations in enzymes (including those responsible for DNA demethylation), or caused by alternative gene splicing or breakpoint mutations. Cancer may be caused by upregulation of receptors. Cancer may be associated with abnormal expression from kinase genes and / or tyrosine kinase receptor genes, such as cytoplasmic kinase genes and / or serine / threonine kinase genes. Cancer may be associated with genetic or epigenetic changes in one or more of the following genes: FIP1L1, PDGFRA, Flt3, ABL1, FGFR1 and cKIT. Cancer may be associated with genetic or epigenetic changes in proteins that are sensitive to ATP mimetics, optionally tyrosine kinase genes such as ABL1, Bruton's tyrosine kinase, cKIT, FGFR1, PDGFRA and PDGFRB. Tyrosine kinase genes (ABL1, Brutons, cKIT, FGFR1, and PDGFRA) are often classified as functional oncogenes when expressed. Genetic or epigenetic changes in proteins that are sensitive to ATP mimetics may be due to changes in the expression of genes that cause upregulation of proteins that are sensitive to ATP mimetics. For example, FIP1L1 is thought to directly upregulate PDGFRA mRNA expression.

[0011] The cancer may be leukemia, myeloproliferative neoplasm, tumor, lung cancer or ovarian cancer. The cancer is selected from idiopathic hypereosinophilic syndrome (iHES), chronic and acute eosinophilic leukemia, chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), PDGFRA positive non-small cell lung cancer (NSCLC), glioblastoma (including glioblastoma multiforme and astrocytoma), prostate cancer, advanced ovarian cancer, gastrointestinal stromal tumor (GIST) and renal cell carcinoma.

[0012] Categorized chromosomal interactions The present invention relates to the classification of chromosomal interactions, such as those associated with cancer and / or responsiveness to tyrosine kinase inhibitor therapy. The chromosomal interactions affect or are associated with disease aspects, such as in any of the disease states mentioned herein. The chromosomal interactions may affect or be associated with disease susceptibility, responsiveness to therapy, or likelihood of relapse. The chromosomal interactions may affect or be associated with prognosis of patients and / or subgroups of patients. Specific chromosomal interactions, genes and regions are disclosed herein, and in one embodiment, the chromosomal interactions, or the chromosomal interactions in those genes and regions, can be classified. Preferred regions are disclosed as ranges in table la. Specific ligated sequences are disclosed herein. Classification of chromosomal interactions may require detection of such ligated sequences or their homologs and / or fragments.

[0013] Preferred chromosomal interactions, genes and regions (genomic locations) are shown in the tables, including Tables 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14. Further preferred chromosomal interactions are those that can be defined or detected using any of the nucleic acids mentioned herein, such as probes or primer pairs.

[0014] The chromosomal interactions being classified may or may not be those that exist between a gene (including a coding sequence) and its regulatory region, such as a promoter.

[0015] Chromosomal interactions can be associated with gene deregulation, e.g., changes in activity (e.g., increases or decreases) in enhancers. Chromosomal interactions can be associated with mutations, e.g., breakpoint mutations, that result in fusion genomic (chromosomal) products that may or may not lead to expression of a fusion protein with altered activity.

[0016] Breakpoint mutations are: - may be any of the mutations described herein, or -may be within, and may be, or may include, any of the genes described herein; or -Breakpoint mutations associated with or causing cancer It could be.

[0017] Breakpoint mutations may be at least 1,000 nucleotides, 10,000 nucleotides, 50,000 nucleotides, 100,000 nucleotides, 500,000 nucleotides, for example at least 800,000 nucleotides in length, which represents the length of the deleted fragment.

[0018] prognosis As used herein, prognosis refers to predicting the likely course of a medical condition, such as one or more outcomes. Prognostic factors are clinical or biological characteristics that can be objectively measured, for example in treated or untreated individuals, and provide information about the likely outcome of a cancer disease. Predictors can provide information about the likely benefit from treatment (e.g., in terms of either tumor shrinkage or survival). Such predictors can be used to identify subpopulations of patients that are most likely to benefit from a given therapy. Markers can have characteristics that are associated with prognosis and predict the likelihood of benefiting from treatment.

[0019] Kinase The present invention may relate to changes in kinase genes or kinase receptor genetic alterations, such as changes in expression and / or changes in epigenetic morphology and / or genetic (genomic) changes, which are associated with and / or cause cancer. Thus, typically, cancer can be associated with abnormal expression of kinase genes and / or tyrosine kinase receptors. In one embodiment, cancer is associated with abnormal expression of cytoplasmic tyrosine kinases (e.g., ABL1) and / or cytoplasmic kinases (e.g., serine / threonine kinases). The term "abnormal expression" may include upregulation or downregulation, or may include expression of different proteins.

[0020] In this context, a "kinase" can be functionally defined as one that undergoes a conformational change during the transfer of ATP to other proteins in the nucleus, cytoplasm or cell membrane, or any other cellular location, including extracellular locations. Examples of related kinase families include receptor tyrosine kinases (e.g., PDGFRA) that are found on the cell surface, and non-receptor kinases such as cytoplasmic tyrosine kinases (e.g., ABL1) and serine / threonine kinases.

[0021] epigenetic interactions As used herein, the term "epigenetic" interactions typically refer to interactions between distant regions on chromosomes, which in one embodiment are dynamic, being altered, formed, or disrupted depending on the state of the chromosomal regions.

[0022] In certain methods of the present invention, chromosomal interactions are detected by first generating a ligated nucleic acid that contains sequences from both regions of the chromosome that are part of the interaction.In such methods, the regions can be cross-linked by any suitable means.In a preferred embodiment, the interaction is cross-linked using formaldehyde, but can also be cross-linked by any aldehyde, or D-biotinyl-e-aminocaproic acid-N-hydroxysuccinimide ester or digoxigenin-3-O-methylcarbonyl-e-aminocaproic acid-N-hydroxysuccinimide ester.Paraformaldehyde can be used and can cross-link DNA strands that are 4 angstroms apart.

[0023] Chromosomal interactions may reflect the state of a chromosomal region, for example, if it is transcribed or repressed in response to changes in physiological conditions. Chromosomal interactions that are specific to a subgroup as defined herein have been found to be stable and thus provide a reliable means of measuring the difference between two subgroups.

[0024] In addition, chromosomal interactions specific to traits (such as disease states) usually occur earlier in biological processes compared to other epigenetic markers, such as changes to methylation or binding of histone proteins. Thus, the method of the present invention can detect at an early stage of biological processes. This allows for early intervention (e.g., treatment), which can be more effective as a result. Furthermore, there is little variation in the relevant chromosomal interactions between individuals in the same subgroup.

[0025] The location and causes of epigenetic interactions Epigenetic chromosomal interactions may include regions of chromosomes that have been shown to overlap or associate or code for undescribed genes, but may equally be intergenic regions.The chromosomal interactions detected in the present invention may be caused by changes to the underlying DNA sequence due to environmental factors, DNA methylation, non-coding antisense RNA transcripts, non-mutagenic carcinogens, histone modifications, chromatin remodeling and specific local DNA interactions.The same chromosomal interaction may be caused by different factors in different subjects.For example, a particular chromosomal interaction may be caused by changes in DNA methylation, for example, due to a mutation in IDH in a region of a chromosome that is different from where the interaction is observed.The same chromosomal interaction may be caused by changes to the underlying sequence, for example, a deletion in the same chromosomal region where the interaction is observed.

[0026] The changes that result in chromosomal interactions can be caused by changes to the underlying nucleic acid sequences that do not themselves directly affect gene products or the mode of gene expression. Such changes can be, for example, SNPs inside and / or outside genes, gene fusions and / or deletions of intergenic DNA, microRNAs, and non-coding RNAs. For example, it is known that almost 20% of SNPs are in non-coding regions, and thus the described methods are useful in non-coding contexts. The regions of chromosomes that come together to form interactions can be less than 5 kb, 3 kb, 1 kb, 500 base pairs, or 200 base pairs apart on the same chromosome. The regions of chromosomes that come together to form interactions can be more than 5 kb, 10 kb, 50 kb, 100 kb, 200 kb, 500 kb, or 800 kb apart on the same chromosome, for example 800 kb to 1,200 kb, such as 900 kb to 1,000 kb apart. Any such values ​​and ranges disclosed herein refer to normal chromosomes (without breakpoint mutations) or to chromosomes carrying breakpoint mutations.

[0027] The chromosomal interaction detected is preferably within any of the genes mentioned herein, but can also be upstream or downstream of the gene, for example up to 50,000, up to 30,000, up to 20,000, up to 10,000 or up to 5000 bases upstream or downstream from the gene or coding sequence.

[0028] Type of clinical situation The aim of the present invention is to allow the detection of chromosomal interactions associated with characteristics that define subgroups in a population. For example, this technology allows stratification based on biomarkers of specific phenotypes (e.g., associated with a medical condition), i.e., by recognizing specific chromosomal conformation signatures and / or changes in those specific signatures. The characteristics that define the subgroups are associated with cancer prognosis. The method of the present invention can be used in the context of specific characteristics associated with a disease, such as responsiveness to treatment, identifying the most effective therapy / drug, monitoring the course of a disease, identifying predisposition to a disease, identifying the presence of co-morbidities and / or the likelihood of recurrence. Thus, the method may or may not be used for diagnosing the presence of a specific condition. In one embodiment, the present invention can be used, for example, to monitor response to treatment on an ongoing basis. The method of the present invention can be used to classify loci where the mechanism of the disease is unknown, unclear, or complex. The detection of chromosomal interactions provides an efficient way to follow changes at different regulatory levels, some of which are complex. For example, in some cases, about 37,000 non-coding RNAs can be activated by a single impulse.

[0029] Characteristics associated with prognosis The trait can be responsive to tyrosine kinase inhibitor therapy. The trait can be abnormal expression from kinase genes and / or from tyrosine kinase genes, for example, the trait can be upregulation of tyrosine kinase expression. Kinases known to be associated with cancer prognosis include receptor tyrosine kinases (e.g., PDGFRA), non-receptor kinases, cytoplasmic tyrosine kinases (e.g., ABL1) and serine / threonine kinases on the cell surface. The trait can be abnormal expression from kinase genes that are responsive or encode gene products that are responsive to known inhibitors, such as tyrosine kinase inhibitors. The trait can be genetic or epigenetic changes in genes that are responsive or encode gene products that are responsive to tyrosine kinase inhibitors. The trait can be genetic or epigenetic changes in one or more of the following genes: FIP1L1, PDGFRA, Flt3, ABL1, FGFR1 and cKIT.

[0030] The property can be responsiveness to a drug that is an ATP mimetic. Tyrosine kinase genes (e.g., ABL1, Brutons, cKIT, FGFR1, PDGFRA and PDGFRB) encode proteins that are sensitive to ATP mimetics.

[0031] The characteristic may be response to a specific treatment and / or prophylaxis (particularly a specific drug treatment and / or prophylaxis), such as a tyrosine kinase inhibitor, optionally where the drug is known to target a receptor tyrosine kinase, such as PDGFRA, preferably one or more from the group including dasatinib, crenolanib, dovitinib and imatinib. The tyrosine kinase inhibitor may be cediranib, crenolanib, dasatinib (Sprycel); dovitinib, imatinib (Gleevec); IMC-3G3 (olaratumab, LY3012207) Lartruvo (PDGFRA); masitinib (AB1010), nilotinib (Tasigna); pazopanib; PKC412 (midostaurin, CGP41251); quizartinib; regorafenib; sorafenib (Nexavar); sunitinib (Sutent); vatalanib; S116836. The characteristic may be a predisposition to a particular condition, possibly hypereosinophilia.

[0032] Subgroups and individualized treatment As used herein, "subgroup" preferably refers to a population subgroup (a subgroup within a population), more preferably a subgroup within a population of a particular eukaryote, or a particular animal, such as a mammal (e.g., human, non-human, non-human primate, or rodent, such as mouse or rat). Most preferably, "subgroup" refers to a subgroup within a human population.

[0033] The present invention includes detecting and treating specific subgroups in a population. Within such subgroups, the characteristics discussed herein (such as responsiveness to treatment) are present or absent. The epigenetic interaction differences on chromosomes are generally structural differences that exist at the genome level. The inventors have found that these differ between subsets (e.g., two or at least two subsets) in a given population. Identifying these differences will allow physicians to classify patients as part of one subset of the population as described in the method. Thus, the present invention provides physicians with a method to personalize patient medicine based on epigenetic chromosomal interactions, and also provides more effective alternative treatments, especially for subgroups of patients whose prognosis is affected as a result of being identified as part of said subgroup.

[0034] Typically, the subgroup is at least 1%, 5%, 10%, 30%, 50% or 80% of the population. The population can be a general population. The population can be a cancer patient group, where the cancer can optionally be any one of the following cancers: iHES, chronic and acute eosinophilic leukemia, chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), PDGFRA positive non-small cell carcinoma (NSCLC), glioblastoma including glioblastoma multiforme and astrocytoma, prostate cancer, advanced ovarian cancer, gastrointestinal stromal tumor (GIST) and renal cell carcinoma. One of the more subgroups can be any of the cancers listed above, and the method of determining the prognosis of cancer can be performed on a subject with any of the cancers.

[0035] Generation of ligated nucleic acids Certain embodiments of the present invention utilize ligated nucleic acids, particularly ligated DNA. These contain sequences from both chromosomal interacting regions together, thus providing information about the interaction. The EpiSwitch™ method described herein uses the generation of such ligated nucleic acids to detect chromosomal interactions.

[0036] Thus, the method of the present invention comprises: (i) in vitro cross-linking of epigenetic chromosomal interactions present at chromosomal loci; (ii) optionally isolating the cross-linked DNA from said chromosomal locus; (iii) subjecting the cross-linked DNA to cleavage, e.g., by restriction digestion, with an enzyme that cuts at least once, particularly an enzyme that cuts at least once within the chromosomal locus; (iv) ligating the cross-linked and cleaved DNA ends (particularly to form a DNA loop); and (v) identifying the presence of said ligated DNA and / or said DNA loops, in particular using techniques such as PCR (polymerase chain reaction), to identify the presence of specific chromosomal interactions. The method may include producing a ligated nucleic acid (e.g., DNA) by:

[0037] PCR can be used to detect or identify the ligated nucleic acid, for example the size of the PCR product produced can indicate the specific chromosomal interaction present, and can therefore be used to identify the state of the locus. Those skilled in the art will know many restriction enzymes that can be used to cut DNA in a chromosomal locus of interest. It will be clear that the specific enzyme used will depend on the locus under study and the sequence of the DNA located therein. A non-limiting example of a restriction enzyme that can be used to cut DNA as described in the present invention is TaqI.

[0038] EpiSwitch™ Technology and Other Embodiments The EpiSwitch™ technology relates to the use of microarray EpiSwitch™ marker data in the detection of epigenetic chromosomal conformation signatures specific to a phenotype. Embodiments such as EpiSwitch™ that utilize nucleic acids ligated in a manner as described herein have several advantages. They have low levels of stochastic noise, for example because nucleic acid sequences from a first set of nucleic acids of the invention either hybridize or fail to hybridize with a second set of nucleic acids. This results in two-dimensional results that allow a relatively simple method for measuring complex mechanisms at the epigenetic level. The EpiSwitch™ technology also has short processing times and low costs. In one embodiment, processing times are between 3 and 6 hours.

[0039] Samples and sample processing The sample comprises DNA from an individual. Usually, it comprises cells. In one embodiment, the sample is obtained by minimally invasive means, and may be, for example, blood. The DNA can be extracted and cut with standard restriction enzymes. This can predetermine which chromosome conformations are retained and detected with the EpiSwitch™ platform. In one embodiment, where the sample is a blood sample previously obtained from the patient, the described method is advantageous because the procedure is minimally invasive. For synchronization of chromosome interactions between tissues and blood, including horizontal transfer, blood samples can be used to detect chromosome interactions in tissues, such as tissues associated with a disease. For certain conditions, such as cancer, genetic noise due to mutations can affect the chromosome interaction "signal" in the relevant tissue, and therefore using blood is advantageous.

[0040] Characteristics of nucleic acids relevant to the present invention The nucleic acids made or detected in the embodiments of the invention may be the same as the first and second nucleic acids referred to herein, or may have any of the properties of the first and second nucleic acids. The nucleic acids of the invention typically comprise two portions, each containing a sequence from one of two regions of a chromosome that together form a chromosomal interaction. Typically, each portion is at least 8, 10, 15, 20, 30 or 40 nucleotides in length, for example 10-40 nucleotides in length. Preferred nucleic acids comprise a sequence from any of the genes referred to in any of the tables. Preferred nucleic acids bind to any of the specific probe or primer sequences referred to herein. Preferably, the nucleic acid is DNA. Where a specific sequence is defined, it is understood that the invention may use a complementary sequence as required in a particular embodiment.

[0041] The second set of nucleic acids - "index" sequences The second set of nucleic acid sequences has the function of being a set of index sequences, and is essentially a set of nucleic acid sequences suitable for identifying subgroup-specific sequences. They may represent "background" chromosomal interactions, and may or may not be selected in any way. They are generally a subset of all possible chromosomal interactions.

[0042] The second set of nucleic acids can be derived by any suitable method. They can be derived from computation or they can be based on chromosomal interactions in an individual. They typically represent a larger population than the first set of nucleic acids. In one particular embodiment, the second set of nucleic acids represents all possible epigenetic chromosomal interactions in a particular set of genes. In another particular embodiment, the second set of nucleic acids represents a majority of all possible epigenetic chromosomal interactions present in the population described herein. In one particular embodiment, the second set of nucleic acids represents at least 50% or at least 80% of epigenetic chromosomal interactions in at least 20, 50, 100 or 500 genes, for example, between 20 and 100 or between 50 and 500 genes.

[0043] The second set of nucleic acids typically represents at least 100 possible epigenetic chromosomal interactions that may possibly modify, regulate or in some way mediate the disease state / phenotype in the population. The second set of nucleic acids may represent chromosomal interactions that affect the disease state in the species, including, for example, nucleic acid sequences that code for cytokines, kinases, or regulators associated with any disease state, disease predisposition or disease phenotype. The second set of nucleic acids typically includes sequences that represent epigenetic interactions associated with and unassociated with the trait that defines the subgroup.

[0044] In a particular embodiment, the second set of nucleic acids is at least partially derived from naturally occurring sequences in the population, typically obtained by computer-based methods. The nucleic acids may further comprise single or multiple mutations compared to the corresponding portions of the nucleic acids present in the naturally occurring nucleic acids. Mutations include deletions, substitutions and / or additions of one or more nucleotide base pairs. In one particular embodiment, the second set of nucleic acids may comprise sequences representing homologs and / or orthologs having at least 70% sequence identity to the corresponding portions of the nucleic acids present in the naturally occurring species. In another particular embodiment, at least 80% sequence identity or at least 90% sequence identity to the corresponding portions of the nucleic acids present in the naturally occurring species is provided.

[0045] A second set of properties of nucleic acids In one particular embodiment, the second set of nucleic acids has at least 100 different nucleic acid sequences, preferably at least 1000, 2000 or 5000 different nucleic acid sequences, up to 100,000, 1,000,000 or 10,000,000 different nucleic acid sequences. A typical number is between 100 and 1,000,000, for example between 1,000 and 100,000 different nucleic acid sequences. All of these, or at least 90% or at least 50%, correspond to different chromosomal interactions.

[0046] In one particular embodiment, the second set of nucleic acids represents chromosomal interactions at at least 20 different loci or genes, preferably at least 40 different loci or genes, and more preferably at least 100, at least 500, at least 1000 or at least 5000 different loci or genes, for example 100-10,000 different loci or genes. The length of the second set of nucleic acids is suitable to specifically hybridize to the first set of nucleic acids according to Watson-Crick base pairing, allowing identification of chromosomal interactions specific to the subgroup. Typically, the second set of nucleic acids comprises two portions that correspond in sequence to two chromosomal regions that together form a chromosomal interaction. The second set of nucleic acids typically comprises a nucleic acid sequence that is at least 10, preferably 20, and more preferably 30 bases (nucleotides) long. In another embodiment, the nucleic acid sequence can be up to 500, preferably up to 100, and more preferably up to 50 base pairs long. In a preferred embodiment, the second set of nucleic acids comprises a nucleic acid sequence of 17-25 base pairs. In one embodiment, at least 100, 80% or 50% of the second set of nucleic acid sequences have a length as described above. Preferably, the different nucleic acids do not have overlapping sequences, e.g., at least 100%, 90%, 80% or 50% of the nucleic acids do not have the same sequence over at least 5 contiguous nucleotides.

[0047] The same set of second nucleic acids can be used with different sets of first nucleic acids representing subgroups of different properties, assuming that the second set of nucleic acids acts as an "index", i.e., the second set of nucleic acids They potentially represent a "universal" collection of nucleic acids that can be used to identify chromosomal interactions associated with different traits.

[0048] First set of nucleic acids The first set of nucleic acids is usually from an individual known to be in two or more different subgroups defined by the presence or absence of a characteristic associated with a prognostic companion epigenetic test, such as any of such characteristics mentioned herein. The first nucleic acid can have any of the characteristics and the characteristics of the second set of nucleic acids mentioned herein. The first set of nucleic acids is usually from a sample from an individual who has undergone treatment and processing as described herein, particularly the EpiSwitch™ crosslinking and cleavage step. Typically, the first set of nucleic acids is all or at least 80% or 50% of the chromosomal interactions present in the sample taken from the individual.

[0049] Typically, the first set of nucleic acids represents a smaller population of chromosomal interactions across the loci or genes represented by the second set of nucleic acids compared to the chromosomal interactions represented by the second set of nucleic acids, i.e., the second set of nucleic acids represents a background or index set of interactions at a given set of loci or genes.

[0050] In one embodiment, the first set of nucleic acids is labeled, typically with nucleic acids from different subgroups being labeled with different labels, allowing them to be distinguished in the detection method.

[0051] nucleic acid The nucleic acids described herein may be in the form of a library of nucleic acids comprising at least 200, at least 500, at least 1000, at least 5000 or at least 10000 different nucleic acids of the invention, e.g., "second" nucleic acids. The invention provides a specific library of nucleic acids, typically comprising at least 200 different nucleic acids. The library may be in the form of an array of bound nucleic acids.

[0052] Hybridization The present invention requires a means for hybridizing the fully or partially complementary nucleic acid sequences from the first set of nucleic acids and the second set of nucleic acids. In one embodiment, all of the first set of nucleic acids are contacted with all of the second set of nucleic acids in a single assay, i.e., in a single hybridization step. However, any suitable assay can be used.

[0053] Labeled Nucleic Acids and Hybridization Patterns The nucleic acid referred to herein may preferably be labeled with an independent label, such as a fluorophore (fluorescent molecule) or a radioactive label, which aids in successful hybridization detection.Certain labels can be detected under UV light.For example, the hybridization pattern on the array described herein represents the difference in epigenetic chromosomal interactions between two subgroups, thus providing a method for comparing epigenetic chromosomal interactions and determining which epigenetic chromosomal interactions are specific to subgroups in the population of the present invention.

[0054] The term "pattern of hybridization" refers broadly to the presence or absence of hybridization between a first and second set of nucleic acids, i.e., which particular nucleic acids from the first set hybridize to which particular nucleic acids from the second set, and thus is not limited to any particular assay or technique, or the need to have a surface or array capable of detecting the "pattern."

[0055] Specific status and selection of subgroups By focusing on chromosomal interactions, and changes in chromosomal interactions, the inventors have identified a patient population that may be missed using routine diagnostic methods and that may respond to potentially life-saving diagnostic and therapeutic interventions using tyrosine kinase inhibitors (TKIs).

[0056] In one embodiment, the method of the present invention detects the responsiveness to tyrosine kinase inhibitor therapy, for example, an inhibitor that is an ATP mimetic.Preferably, the responsiveness of cancer to tyrosine kinase inhibitor therapy is detected in patients with increased eosinophils.Preferably, the cancer is iHES, chronic and acute eosinophilic leukemia, acute myeloid leukemia (AML), PDGFRA positive non-small cell carcinoma, glioblastoma including glioblastoma multiforme and astrocytoma, prostate cancer, advanced ovarian cancer or gastrointestinal stromal tumor (GIST).In such an embodiment, detection of chromosomal interactions in PDGFRA and / or FIP1L1 is preferred, for example any specific interactions described herein (for example, by reference to specific primers and / or probes).

[0057] Preferably, the presence or absence of any chromosomal interaction within any relevant gene mentioned herein is detected, for example, in at least 1, 2, 3, 4, 5 or 6 genes. Preferably, the presence or absence of a chromosomal interaction represented by any specific primer and / or probe sequence disclosed herein is determined in the method. These numbers of genes or chromosomal interactions can be used in any of the different embodiments mentioned herein.

[0058] The present invention provides a method comprising detecting the presence or absence of a chromosomal interaction, typically 1 to 5, or 5 to 20, or 5 to 500 such interactions, to determine the presence or absence of a trait in an individual. Preferably, the chromosomal interaction is in any of the genes mentioned herein.

[0059] 3C interactions and cancer Different embodiments of the invention may relate to any cancer or gene mentioned herein, such as those listed below.

[0060] The inventors have found 3C interactions in ABL1, Bruton's tyrosine kinase, cKIT, FGFR1, FlPL1, FLT3 and PDGFRA, which are associated with cancers including breast cancer, ovarian cancer, leukemia, glioma, lymphoma and carcinoma.

[0061] Typically, the interactions associated with or identified using the methods described herein are associated with any of the following conditions: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), CML-blast crisis, gastrointestinal stromal tumor (GIST), myelodysplastic syndrome (MDS), myeloproliferative disorders (myeloproliferative neoplasms, MPN), X-linked agammaglobulinemia (XLA), B-cell malignancies, NHL, lymphoma (all types), myeloma, relapsed mature B-cell neoplasms, chronic graft-versus-host disease, relapsed hairy cell leukemia, relapsed or refractory solid tumors, refractory mantle cell lymphoma, amplified esophagogastric cancer, rheumatoid arthritis, mastocytosis, mast cell leukemia, prostate tumor, advanced melanoma, mutated malignant melanoma, secondary (2nd Line), unresectable or metastatic gastrointestinal stromal tumor (GIST), expressing malignant mesothelioma, advanced, platinum-refractory ovarian cancer, recurrent ovarian epithelial carcinoma, fallopian tube, or primary peritoneal cancer, ovarian tumor of low malignant potential, uterine papillary serous carcinoma, advanced small cell lung cancer, locally advanced nasopharyngeal carcinoma, recurrent / refractory non-Hodgkin's lymphoma, metastatic renal cell carcinoma, metastatic gastrointestinal pancreatic neuroendocrine tumor, recurrent ovarian clear cell carcinoma, esophageal squamous cell carcinoma, persistent uterine cancer, breast cancer, thyroid cancer, oral adenoma, acute leukemia, prostate tumor, recurrent head and neck cancer with translocation FGFR1-3, mutation, or amplification, recurrent malignant glioma expressing FGFR-TACC gene fusion, advanced non-small cell lung cancer.

[0062] In one embodiment, the interactions related to or identified using the methods described herein are associated with any of the following conditions: iHES, non-small cell lung cancer (NSCLC), colorectal cancer, metastatic melanoma, renal cell carcinoma, refractory Hodgkin's lymphoma, previously treated ovarian cancer, locally advanced nasopharyngeal carcinoma, refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), Sumitinib-failed gastrointestinal stromal tumor (GIST). Preferred conditions are glioma, acute myeloid leukemia and breast cancer, iHES and chronic leukemia.

[0063] For example, interactions in ABL1, a cytoplasmic tyrosine kinase gene located at 9q34, are associated with the following diseases: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), breast cancer, (GIST), myelodysplastic syndromes (MDS) or myeloproliferative disorders (myeloproliferative neoplasms, MPN).

[0064] Interactions with Bruton's tyrosine kinase, e.g., a cytoplasmic tyrosine kinase gene located at Xq22.1, have been linked to the following diseases: X-linked agammaglobulinemia (XLA), B-cell malignancies, NHL, lymphoma (all types), myeloma, chronic lymphocytic leukemia, relapsed mature B-cell neoplasms, chronic graft-versus-host disease, relapsed hairy cell leukemia, relapsed or refractory solid tumors, refractory mantle cell lymphoma, amplified esophagogastric cancer, and rheumatoid arthritis.

[0065] Interactions with cKIT, a receptor tyrosine kinase gene located at 4q12, have been implicated in the following diseases: mastocytosis and mast cell leukemia, as well as prostate tumors, advanced melanoma, mutated malignant melanoma, secondary unresectable or metastatic gastrointestinal stromal tumors (GIST), expressed malignant mesothelioma, advanced, platinum-refractory ovarian cancer, recurrent ovarian epithelial carcinoma, fallopian tube, or primary peritoneal cancer, or ovarian low malignant potential tumor, advanced stage small cell lung cancer, locally advanced nasopharyngeal carcinoma, recurrent / refractory non-Hodgkin's lymphoma, metastatic renal cell carcinoma, metastatic gastrointestinal pancreatic neuroendocrine tumors, recurrent ovarian clear cell carcinoma, esophageal squamous cell carcinoma, persistent uterine cancer, and breast cancer.

[0066] For example, interactions in FGFR1, a receptor tyrosine kinase gene located at 8pll, have been linked to the following diseases: thyroid cancer, oral adenomas, chronic leukemia, acute leukemia, prostate tumors and breast cancer, recurrent head and neck cancers with translocations FGFR1-3, mutations or amplifications, recurrent malignant gliomas expressing FGFR-TACC gene fusions, and advanced non-small cell lung cancer.

[0067] Interactions in FIP1L1, a polyadenylation specificity factor that is often fused to PDGFRA (eg, 4q12), have been associated with the following diseases: iHES, chronic leukemia.

[0068] For example, interactions in the FLT3 receptor tyrosine kinase gene located at 13q11-12.2 have been associated with the following diseases: chronic leukemia, acute myeloid leukemia and breast cancer, iHES, chronic leukemia, non-small cell lung cancer (NSCLC), colorectal cancer, metastatic melanoma or renal cell carcinoma, glioma, refractory Hodgkin lymphoma, previously treated ovarian cancer, locally advanced nasopharyngeal carcinoma, refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), and sumitinib-failed gastrointestinal stromal tumor (GIST).

[0069] For example, interactions in PDGFRA, a receptor tyrosine kinase gene located at 4q12, have been linked to the following diseases: glioma, chronic leukemia, acute myeloid leukemia, breast cancer, and iHES.

[0070] Tested specimens The individual being tested may or may not have any symptoms of any disease state or trait mentioned herein. The individual may be at risk for any such condition or trait. The individual may be at risk for the trait. The individual may have a worse prognosis for the trait and may require specific therapy for the trait. The individual may have recovered from or be in the process of recovering from the condition or trait. The individual is preferably a mammal, such as a primate, human, non-human mammal, or rodent. The individual may be male or female. The individual may be 30 years of age or older. The individual may be 29 years of age or younger.

[0071] Any of the genes, loci, regions and nucleic acids discussed herein may have or be derived from any of the individual types referred to herein.

[0072] Favorable gene regions, loci, genes and chromosomal interactions For all aspects of the present invention, preferred gene regions, loci, genes and chromosomal interactions are mentioned herein.Typically, in the method of the present invention, chromosomal interactions are detected from at least 1, 2, 3, 4, 5 or 6 related genes listed herein.Preferably, the presence or absence of at least 1, 2, 3, 4, 5 or 6 related specific chromosomal interactions represented by primer and / or probe sequences mentioned herein are detected.

[0073] The region may be upstream or downstream of any of the genes referred to herein, for example, 50 kb upstream or 20 kb downstream from the coding sequence.

[0074] In one embodiment, the chromosomal interaction to be detected is present at any of the positions or regions shown in the table. When the ligation product is detected in the method, the sequence shown in any of the primer or probe sequences disclosed herein can be detected. Thus, typically, sequences from both regions of the ligation product (i.e., from both sites of the chromosomal interaction) can be detected. In a preferred embodiment, the method uses primers and / or probes that contain or consist of the same or complementary sequences as the primers and / or probes disclosed herein. In some embodiments, primers and / or probes that contain sequences that are homologous to any of the primer and / or probe sequences shown herein are used.

[0075] Detection of ligation products by quantitative PCR (qPCR) In one embodiment, the ligated sequence related to chromosomal interaction is quantitatively detected, for example by using fluorescence detection.This embodiment can be carried out for any ligated sequence disclosed herein or related to classification / detection method disclosed herein, but is not limited to such sequence or method.Therefore, the embodiment related to qPCR can be carried out to detect any ligated sequence that can have any characteristic mentioned herein, including the sequence from the region of chromosome that is combined and has any chromosomal interaction.

[0076] Thus, the present invention provides a method for quantitatively detecting ligated sequences associated with a chromosomal interaction using a probe that is detectable upon activation during a PCR reaction, said ligated sequences comprising sequences from two chromosomal regions which together undergo an epigenetic chromosomal interaction, comprising contacting the ligated sequences with the probe during a PCR reaction and detecting the degree of activation of the probe, wherein the probe binds to the ligation site.

[0077] The primer and probe sequences can be any such disclosed specific sequence or homologues and / or fragments of the specific sequence. The primer sequence can typically amplify the ligation product produced in the process of detecting chromosomal interactions, such as the 3C or EpiSwitch™ method, any such method as disclosed herein, or ligation product. The primer is typically unidirectional. In some cases, the primer sequence is designed to be unique to the ligation product of the 3C interaction in question. The probe can typically specifically bind to a sequence in the ligation product that contains the ligation site. The probe is typically a "hydrolysis" probe that can be cleaved / released from one or more portions to activate the label during the PCR reaction.

[0078] Ligated sequences can be prepared by cross-linking a sample of nucleic acid followed by breaking down the nucleic acid into smaller fragments, for example by enzymatic digestion or by a physical shearing process. A ligation step is then performed. Ligated sequences are typically derived from individuals or cell lines that have undergone treatment and processing as described herein, particularly the EpiSwitch™ cross-linking and cleavage steps. Ligated sequences can be ligated products defined in or produced by any of the methods. The ligation site of the ligated sequence may contain a restriction enzyme recognition sequence for the restriction enzyme used to cleave the cross-linked nucleic acid. A preferred restriction enzyme is TaqI or any modified form of TaqI (e.g., one that recognizes the same restriction site). Ligated DNA molecules can include nucleic acid sequences that are 10-100 nucleotide bases long, or 10-400 nucleotide bases long, or 10-500 nucleotide bases long, or 200-600 nucleotide bases long, or 200-800 nucleotide bases long, or 200-1000 nucleotide bases long.

[0079] Preferably, only one set of primers (i.e., two PCR primers that can be amplified together) is used in the detection, and nested PCR with more than one set of primers is not performed. Preferably, the primers are unidirectional. Even more preferably, the primer sequences are selected to be specific to the 3C interaction in question. In one embodiment, the detection method is performed in the presence of other nucleic acids (e.g., other ligation products) that are not amplified and / or to which the probe does not bind. Typically, the other nucleic acids (e.g., ligation products) may be at least 10%, 30% or at least 50% of the nucleic acids or ligation products present.

[0080] Conditions detected by qPCR The qPCR method described herein can be used to detect chromosomal interactions in any situation where they are relevant, for example, any situation described.It can typically be used to detect chromosomal interactions related to, for example, subgroups as defined herein.It can be used to detect changes in chromosomal interactions and / or chromosomal interactions related to mutations, changes in expression from genes or deregulation of genes.

[0081] The qPCR method described herein can be used to detect chromosomal interactions, where the sequences from two chromosomal regions that are epigenetic chromosomal interactions together are at least 1000 base pairs apart, or at least 10,000 base pairs apart, or at least 100,000 base pairs apart in chromosomes.The qPCR method described herein can be used to detect long-range chromosomal interactions, where the sequences from two chromosomal regions that are epigenetic chromosomal interactions together are more than 100,000 base pairs apart, and thus the interaction produces a DNA loop of more than 100 kilobases, sometimes more than 500 kilobases, and preferably more than 900 kilobases.The qPCR method described herein can be used to detect long-range chromosomal interactions associated with genetic or epigenetic changes in genes that respond to tyrosine kinase inhibitor therapy, such as PDGFRA.

[0082] qPCR probe design / construction Probes for use in qPCR reactions can be designed to specifically bind to the ligated DNA molecules adjacent to the ligation site and at a site on the ligated DNA molecule that includes the ligation site and optionally has a sequence complementary to a sequence from each of the chromosomal regions. The probe has a sequence that spans the junction of both fragments and binds, for example, at least 5, 10 or 20 nucleotide bases 5' and 3' to the ligation site. The probe can comprise a nucleic acid sequence between 10 and 40 nucleotide bases in length, or preferably between 10 and 35 nucleotide bases in length, or more preferably between 20 and 30 nucleotide bases in length. The probe can have a sequence that has at least 70% homology / identity to the sequence of the ligated DNA molecule, or other level of identity as defined herein.

[0083] Labeling of qPCR probes The probe is generally labeled with a detectable label that has an inactive and an active state, so that it is only detected when activated.The degree of activation will be related to the degree of template (ligated product) present in the PCR reaction.Detection can be carried out during all or part of PCR, for example, during at least 50% or 80% of the cycles of PCR.

[0084] The probe may comprise a fluorophore covalently attached to one end of the oligonucleotide and a quencher attached to the other end of the nucleotide, such that the fluorescence of the fluorophore is quenched by the quencher. In one embodiment, the fluorophore is attached to the 5' end of the oligonucleotide, and the quencher is covalently attached to the 3' end of the oligonucleotide. Fluorophores that can be used in the method of the present invention include FAM, TET, JOE, Yakima Yellow, HEX, Cyanine3, ATTO550, TAMRA, ROX, Texas Red, Cyanine3.5, LC610, LC640, ATTO647N, Cyanine5, Cyanine5.5 and ATTO680. Quenchers that can be used with suitable fluorophores include TAM, BHQ1, DAB, Eclipse, BHQ2 and BBQ650, and optionally the fluorophore is selected from HEX, Texas Red and FAM. Preferred combinations of fluorophores and quenchers include FAM and BHQ1 and Texas Red and BHQ2. Other preferred combinations are shown in Table 3.

[0085] Use of probes in qPCR assays The hydrolysis probes of the present invention are typically temperature gradient optimized with concentration-matched negative controls. Preferably, a single-step PCR reaction is optimal. More preferably, a standard curve is calculated. The advantage of using a specific probe that binds across the junction of the ligated sequences is that specificity for the ligated sequences can be achieved without using a nested PCR approach. The methods described herein allow accurate and precise quantification of low copy number targets. The target ligated sequences can be purified, e.g., gel purified, prior to temperature gradient optimization. The target ligated sequences can be sequenced. Preferably, the PCR reaction is performed using about 10 ng, or 5-15 ng, or 10-20 ng, or 10-50 ng, or 10-200 ng of template DNA. The forward and reverse primers are designed such that one primer binds to one of the sequences of the chromosomal regions represented in the ligated DNA sequence and the other primer binds to the other chromosomal region represented in the ligated DNA sequence, e.g., by being complementary to a sequence.

[0086] Selection of ligated DNA targets The present invention provides a method of selecting primers and probes for use in a PCR method as defined herein, which comprises selecting primers based on their ability to bind to and amplify a sequence to which they are ligated, and selecting probe sequences based on the properties of the target sequence to which they bind, in particular the curvature of the target sequence.

[0087] Probes are designed / selected to bind to ligated sequences that are typically juxtaposed restriction fragments spanning the restriction site. In one embodiment of the present invention, the expected curvature of possible ligated sequences associated with a particular chromosomal interaction is calculated using, for example, certain algorithms referenced herein. Curvature can be expressed as degrees per helical turn, for example 10.5° per helical turn. Ligated sequences are selected for targeting when the ligated sequence has a curvature trend peak score of at least 5° per helical turn, typically at least 10°, 15° or 20° per helical turn, for example 5°-20° per helical turn. Preferably, the curvature score per helical turn is calculated for at least 20, 50, 100, 200 or 400 bases, for example 20-400 bases upstream and / or downstream of the ligation site. Thus, in one embodiment, the target sequence in the ligated product has any of these levels of curvature. Target sequences can also be selected based on the lowest thermodynamic structural free energy.

[0088] Preferred embodiments for sample preparation and chromosomal interaction detection Methods for sample preparation and chromosome conformation detection are described herein. Optimized (conventional) versions of these methods can be used, for example, as described in this section.

[0089] Typically, the sample contains at least 2 × 10 5 Contains cells. Samples are up to 5 × 10 5 In one embodiment, the sample may contain 2×10 cells. 5 ~5.5×10 5 Contains cells. Cross-linking of epigenetic chromosomal interactions present at chromosomal loci is described herein. This can be performed before cell lysis occurs. Cell lysis can be performed for 3-7 minutes, for example, 4-6 or about 5 minutes. In some embodiments, cell lysis is performed for at least 5 minutes and less than 10 minutes.

[0090] Digestion of DNA with restriction enzymes is described herein. Typically, DNA restriction is carried out at about 55° C. to about 70° C., e.g., about 65° C., for a period of about 10 to 30 minutes, e.g., about 20 minutes.

[0091] Preferably, frequent cutter restriction enzymes are used, which result in ligated DNA with an average fragment size of up to 4000 base pairs. In some cases, the restriction enzyme results in fragments of DNA with an average fragment size of about 200-300 base pairs, such as about 256 base pairs. In one embodiment, typical fragment sizes are 200 base pairs to 4,000 base pairs, such as 400-2,000 or 500-1,000 base pairs.

[0092] In one embodiment of the EpiSwitch Method, a DNA precipitation step is not performed between the DNA restriction digestion step and the DNA ligation step.

[0093] DNA ligation is described herein. Typically, DNA ligation is carried out for 5 to 30 minutes, for example, about 10 minutes.

[0094] Proteins in the sample can be enzymatically digested, for example using a proteinase, optionally proteinase K. Proteins can be enzymatically digested for about 30 minutes to 1 hour, for example about 45 minutes. In one embodiment, there is no cross-link reversal or phenol DNA extraction step after protein digestion, for example after proteinase K digestion.

[0095] In one embodiment, PCR detection can detect a single copy of the ligated nucleic acid, preferably with a binary readout for the presence / absence of the ligated nucleic acid.

[0096] Identification of Therapies and Treatments The present inventors have found how chromosomal interactions are relevant to cancer therapy, such as how compounds used in cancer treatment can also directly act on 3C chromosome conformation. For example, ATP mimetic imatinib, known to act directly on activated tyrosine kinases, has been found to directly act on 3C chromosome conformation in imatinib-responsive genes such as cKIT.

[0097] Thus, identification or monitoring of changes in chromosome conformation associated with the target of a known therapeutic agent can be used to identify compounds that cause the same changes in conformation and have the same therapeutic effect. Thus, identification or monitoring of changes in chromosome conformation associated with the target of a known therapeutic agent can be used to identify subjects or cells that are sensitive to treatment with a therapeutic agent or other therapeutic agent that can also cause changes in chromosome conformation.

[0098] Furthermore, the present invention provides therapeutic nucleic acids that can be used to prevent or treat cancer by altering the relevant chromosomal interactions, for example as referred to herein. Such nucleic acids can be DNA or RNA and can function by "interference", such as RNAi.

[0099] Homologs and fragments The present invention includes the use of homologues and / or fragments of the nucleic acids referred to herein, including the specific sequences disclosed herein. Such homologues and / or fragments may have the same binding properties as the original nucleic acid, e.g., be capable of specifically binding to the relevant ligation product.

[0100] Polynucleotide / nucleic acid (e.g., DNA) homologs typically have at least 70% homology, preferably at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% homology, for example over a region of at least 10, 15, 20, 30, 100 or more contiguous nucleotides, or over a portion of the nucleic acid that is from a region of a chromosome involved in a chromosomal interaction. Homology may be calculated based on nucleotide identity (sometimes referred to as "hard homology").

[0101] For example, the UWGCG Package provides the BESTFIT program, which can be used to calculate homology and / or % sequence identity (e.g., used with its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology and / or % sequence identity and / or line up sequences (e.g., as described in Altschul SF (1993) J Mol Evol 36:290-300; Altschul, S,F et al (1990) J Mol Biol 215:403-10) to identify equivalent or corresponding sequences (typically based on their default settings).

[0102] Software for performing BLAST analysis is typically publicly available from the National Center for Biotechnology Information. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy a certain positive threshold score T when aligned with words of the same length in the database sequences. T is called the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds to initiate searches to find HSPs that contain them. The word hits are extended in both directions along each sequence for as long as the cumulative alignment score can be increased. The extension of word hits in each direction is stopped when the cumulative alignment score falls by an amount X from the maximum value reached; when the cumulative score falls below 0 due to the accumulation of one or more negative scoring residual alignments; or when the end of either sequence is reached. The BLAST algorithm parameters W5T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, a BLOSUM62 scoring matrix of 50 (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919), alignments (B) of 10, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

[0103] The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum possibility (P(N)), which provides an indication of the probability that a match between two polynucleotide sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum possibility comparing the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0104] Homologous sequences typically differ by 1, 2, 3, 4 or more bases, for example less than 10, 15 or 20 bases (which may be nucleotide substitutions, deletions or insertions). These changes may be measured over any of the regions previously described in connection with calculating homology and / or % sequence identity.

[0105] Fragments typically have a length that is at least 90%, 80% or 50% of the original sequence. They may have a truncation of at least 5, 8 or 10 nucleotides from the 5' and / or 3' end.

[0106] array The second set of nucleic acids can be bound to an array, and in one embodiment, there are at least 15,000, 45,000, 100,000 or 250,000 different second nucleic acids bound to the array, preferably representing at least 300, 900, 2000 or 5000 loci. In one embodiment, one or more or all of the different populations of second nucleic acids are bound to more than one different region of the array, effectively being repeated on the array, allowing for error detection. The array can be based on the Agilent SurePrint G3 Custom CGH microarray platform. Detection of binding of the first nucleic acid to the array can be performed by a two-color system.

[0107] Treatment Therapeutic agents are referred to herein. The present invention provides agents for use in the prevention or treatment of associated conditions. This may include administering a therapeutically effective amount of the agent to an individual in need. The methods of the present invention can be used to select individuals for treatment. The methods of the present invention, particularly the methods for carrying out prognostic companion epigenetic tests, can be used to administer to individuals identified by the methods an agent that then prevents or treats the associated condition, such as a tyrosine kinase inhibitor, preferably cediranib, crenolanib, dasatinib (Sprycel); dovitinib, imatinib (Gleevec); IMC-3G3 (olaratumab, LY3012207) Lartruvo (PDGFRA); masitinib (AB1010) The therapeutic step may include administering one or more from the group of known tyrosine kinase inhibitors including nilotinib (Tasigna); pazopanib; PKC412 (midostaurin, CGP41251); quizartinib; regorafenib; sorafenib (Nexavar); sunitinib (Sutent); vatalanib; S116836, more preferably from the group including dasatinib, crenolanib, dovitinib and imatinib.

[0108] The formulation of the drug depends on the nature of the drug. The drug is provided in the form of a pharmaceutical composition comprising the drug and a pharma- ceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, such as phosphate buffered saline. Typical oral dosage compositions include tablets, capsules, solutions and suspensions. The drug can be formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration.

[0109] The dosage of the drug can be determined according to various parameters, in particular according to the substance used; the age, weight and condition of the individual to be treated; the route of administration; and the regimen required. The physician will be able to determine the route of administration and dosage required for any particular drug. However, a suitable dosage may be 0.1-100 mg / kg body weight, for example 1-40 mg / kg body weight, taken, for example, 1-3 times per day.

[0110] Forms of material referred to herein Any substance, such as a nucleic acid or therapeutic agent, referred to herein may be in purified or isolated form. It may be in a form different from that found in nature, e.g., they may be present in combination with other substances that are not found together in nature. Nucleic acids (including portions of sequences defined herein) may have sequences different from those found in nature, e.g., having at least one, two, three, four or more nucleotide changes in sequence as described in the section on homology. Nucleic acids may have heterologous sequences at the 5' or 3' end. Nucleic acids may be chemically different from those found in nature, e.g., they may be modified in some way, but preferably still capable of Watson-Crick base pairing. Optionally, nucleic acids are provided in double-stranded or single-stranded form. The present invention provides all of the specific nucleic acid sequences referred to herein, in single-stranded or double-stranded form, and thus includes the complementary strand to any sequence disclosed.

[0111] The present invention also provides a kit for carrying out any process of the present invention, including the detection of chromosomal interactions associated with specific subgroups.Such a kit can include a specific binding agent that can detect associated chromosomal interactions, such as an agent that can detect the ligated nucleic acid produced by the process of the present invention.Preferred agents present in the kit include a probe that can hybridize with ligated nucleic acid or primer pair, such as a hydrolytic probe as described herein, that can amplify ligated nucleic acid in PCR reaction or qPCR reaction.

[0112] The present invention also provides a device capable of detecting relevant chromosomal interactions, preferably comprising any specific binding agent, probe or primer pair capable of detecting chromosomal interactions, such as any such agent, probe or primer pair described herein.

[0113] The nucleic acids referred to herein may be in the form of DNA.

[0114] Specific embodiments The EpiSwitch™ platform technology detects epigenetic regulatory signatures of regulatory changes between normal and abnormal states at loci. The EpiSwitch™ platform identifies and monitors the fundamental epigenetic level of gene regulation associated with the regulatory conformation of human chromosomes, also known as chromosome conformation signatures. Chromosomal signatures are the distinct first step in the cascade of gene deregulation. They are higher order biomarkers that have a unique set of advantages over biomarker platforms that utilize later epigenetic and gene expression biomarkers, such as DNA methylation and RNA profiling.

[0115] EpiSwitch™ Array Assays The custom EpiSwitch™ array screening platform is supplied with four densities of 15K, 45K, 100K, and 250K unique chromosome conformations, and each chimeric fragment is repeated four times on the array, creating effective densities of 60K, 180K, 400K, and 1 million, respectively.

[0116] Custom-designed EpiSwitch™ arrays The 15K EpiSwitch™ array can screen the entire genome, including approximately 300 loci interrogated using the EpiSwitch™ Biomarker discovery technology. The EpiSwitch™ array is built on the Agilent SurePrint G3 Custom CGH microarray platform; this technology offers four densities: 60K, 180K, 400K, and 1,000,000 probes. The density per array is reduced to 15K, 45K, 100K, and 250K, since each EpiSwitch™ probe is presented in quadruplicate, thus allowing for statistical evaluation of reproducibility. The average number of potential EpiSwitch™ markers interrogated per locus is 50; therefore, the number of loci that can be interrogated is 300, 900, 2,000, and 5,000.

[0117] EpiSwitch™ Custom Array Pipeline The EpiSwitch™ array is a two-color system with one set of samples, after EpiSwitch™ library generation, labeled with Cy5 and the other sample (control) labeled with comparison / analysis·Cy3. The arrays are scanned using an Agilent SureScan Scanner and the resulting features are extracted using Agilent Feature extraction software. The data is then processed using the EpiSwitch™ array processing script in R. The arrays are processed using the standard two-color package in Bioconductor: Limma* in R. Array normalization is performed using the normalize intra-array function in Limma*, which is performed using the on-chip Agilent positive control and the EpiSwitch™ positive control. The data is filtered based on Agilent Flag calls to remove Agilent control probes, average the technical replicate probes and analyze them using Limma*. The probes are modeled based on their difference between the two scenarios being compared and then corrected using the False Discovery Rate. Probes with a coefficient of variation (CV) <=30% that is <=-1.1 or =>1.1 and passes a p<=0.1 FDRp value are used for further screening. Further multifactor analysis is performed using the FactorMineR package in R to reduce the probe sets. *Note: LIMMA is a linear model and empirical Bayes process for assessing differential expression variation in microarray experiments. Limma is an R package for the analysis of gene expression data derived from microarrays or RNA-Seq.

[0118] A pool of probes was first selected based on the adjusted p-value, FC and CV<30% (arbitrary cut-off point) parameters for the final picking. Further analysis and the final list are drawn based only on the first two parameters (adj. p-value; FC).

[0119] Statistics Pipeline The EpiSwitch™ screening arrays are processed using the EpiSwitch™ analysis package in R to select high value EpiSwitch™ markers for translation onto the EpiSwitch™ PCR platform.

[0120] Step 1 Probes are selected based on the corrected p-value (False Discovery Rate, FDR), which is the product of a modified linear regression model. Probes with p-values ​​<=0.1 or less are selected and then further reduced by their epigenetic ratio (ER), probes ER must be <=-1.1 or =>1.1 to be selected for further analysis. The final filter is the coefficient of variation (CV), probes must be <=0.3 or less.

[0121] Step 2 The top 40 markers from the statistical list are selected based on their ER for selection as markers for PCR translation. The list is composed of the top 20 markers with the highest negative ER load and the top 20 markers with the highest positive ER load.

[0122] Step 3 The markers, statistically significant probes obtained from step 1, form the basis of an enrichment analysis using hypergeometric enrichment (HE). This analysis allows the reduction of markers from the significant probe list, which, together with the markers from step 2, form the list of probes that are translated into the EpiSwitch™ PCR platform.

[0123] The statistical probes are processed by HE to determine which genetic locations have statistically significant enrichment of probes, indicating which genetic locations are focal points of epigenetic variation.

[0124] The most significant enrichment loci based on corrected p-values ​​are selected for probe list generation. Gene locations with p-values ​​of 0.3 or 0.2 are selected. Statistical probe mapping to these gene locations using markers from step 2 creates high value markers for EpiSwitch™ PCR translation.

[0125] Array design and processing 1. Loci are processed using SII software (currently v3.2): a. Extract the genome sequence at these specific loci (gene sequences with 50kb upstream and 20kb downstream) b. Specify the probability that the sequence in this region is included in the CC c. Cleave the sequence using a specific RE d. Determine which restriction fragments are likely to interact in a particular orientation e. Rank the likelihood that different CCs will interact with each other. 2. Determine the array size and therefore the number of available probe positions (x). 3. Extract x / 4 interactions. 4. For each interaction, define a 30bp sequence for the restriction site from part 1 and a 30bp sequence for the restriction site from part 2. Check that these regions are not repetitive, if so, exclude them and list the next interaction. Together, both 30bp define the probe. 5. A list of x / 4 probes plus defined control probes is generated and replicated 4 times to generate the list that will be generated on the array. 6. Upload the list of probes to the Agilent Sure design website for custom CGH arrays. 7. Design Agilent custom CGH arrays using the probe sets.

[0126] Array Processing 1. Process samples using EpiSwitch™ SOP for template generation. 2. Clean up by ethanol precipitation by the array processing laboratory. 3. Process samples according to Agilent SureTag Complete DNA Labeling Kit - Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis Enzyme Labeling of Blood, Cells or Tissues. 4. Scan using an Agilent C Scanner using Agilent feature extraction software.

[0127] Publications The contents of all publications mentioned herein are incorporated herein by reference and may be used to further define features relevant to the present invention. EXAMPLES

[0128] Example 1. Analysis of chromosomal interactions in cancer preface Current cancer diagnostic methods based on genomic DNA are inefficient, semi-quantitative, and cannot capture all breakpoint variants. Diagnostic methods based on nested RT-PCR require live cells, must be confirmed using other methods, and have complex RNA processing steps. The method developed in this study captures all breakpoint variants, is quantitative, has no RNA stability issues, uses small sample volumes, and has a fast processing time. Therefore, this method reduces the chances of misdiagnosis and incorrect treatment.

[0129] This study also identifies 3C interactions that are therapeutically responsive to tyrosine kinase inhibitors. This forms the basis of a prognostic test that can be used to detect patients treatable with tyrosine kinase inhibitors. Current tests are not accurate or sensitive, for example due to breakpoint variation. Misdiagnosis would result in patients not receiving tyrosine kinase inhibitor therapy but instead receiving steroids, for which they are unresponsive. For example, untreated iHES patients have a poor prognosis.

[0130] We investigated cancer-associated epigenetic interactions and their utility in stratifying patients for treatment with tyrosine kinase inhibitors. Using a high-resolution chromosome-conformation capture or 3C analysis platform known as EpiSwitchTM and quantitative PCR, we mapped, assessed, and quantified the conformational juxtaposition between FIP1L1 and PDGFRA in glioma cell lines with and without IDH mutations. Deregulation of PDGFRA by interstitial deletion at 4q12 and fusion to FIP1L1 associated with chronic eosinophilic leukemia led our group to also investigate whether the same chromosome conformational interactions exist in EOL-1 and other leukemia cell lines.

[0131] We identified select 3C epigenetic interactions associated with mutations by using a high-resolution chromosome conformation capture or 3C analysis platform known as EpiSwitchTM. To optimize primers, we used a temperature gradient in a 96-well plate assay using the Qjagen QIAgility High-Precision Automated PCR System and tested 72 primers in 36 separate temperature gradient PCRs. A total of 20 individual OBD predicted 3C interactions were screened. Where possible, multiple primer sets were used for each predicted interaction. We optimized single-step PCR using 10 ng of target-3C template from two AML cell lines, EOL-1 and HL-60. PCR amplification (of the target) was performed using SYBR detection and concentration-matched negative controls. Negative controls included formaldehyde-free EOL-1 (with digestion and ligation) and normal genomic DNA, which were treated as 3C samples. All PCR products were run on the LabChip. PCR products of the expected size were gel purified (Invitrogen) and sequenced in the forward and reverse primer orientations. Primers were used at 3.2 pmol / μL per reaction with a template concentration of 1 ng / μL per 100 bp. Products showing 100% homology to the expected 3C fragment were carried forward into qPCR design.

[0132] To screen for IDH1 SNP rsll554137 and the IDH1 R132H mutation, 10 ng of 3C template was used with conventional IDH1 genomic primers derived from a scholarly publication; these primer sequences were designed externally and are not included in this application.

[0133] Single-step qPCR was performed using hydrolysis-probe-based qPCR with concentration-matched negative controls. Detection of the B7 462 bp interaction was then optimized using a hydrolysis probe designed against the junction region of the targeted 3C DNA fragment. The probe used in the qPCR assay is specific for the 3C DNA fragment. EOL-1 template (10 ng) was used to optimize the probe in a temperature gradient-based qPCR (58-68 °C). Primers were selected for hydrolysis probe qPCR assay development. The B7 product was used to design a 3C fragment-specific qPCR. Dual-labeled hydrolysis probes targeted with 5'-FAM / BHQl-3' or 5'Texas Red / BHQ2-3' were used to detect the sequenced interaction. The probes were designed to span the junction region of the 3C fragment, thereby ensuring that detection of the 3C product was specific for the FIPL1L1 and PDGFRA interaction. A qPCR standard curve (10 6 -1 copy) was generated from the sequenced products.

[0134] A dual-labeled 5'FAM-BHQl-3' labeled hydrolysis probe was used to detect sequenced interactions. All samples were screened at 20ng and MMP1 copy numbers were recorded. The sequenced PCR product B7 was used to generate a standard curve for qPCR screening. qPCR templates adjusted to 20ng of 3C library DNA were used with concentration-matched negative controls. Controls included 3C libraries derived from adipose biopsies and normal blood. Further negative controls included cell line material without formaldehyde fixation, digested and ligated library material, and normal genomic DNA. This study was performed in accordance with the American Society of Hematology guidelines. Cell lines were provided by ATCC. Patient material with ethical consent was provided by Tissue Solutions (Oxford BioDynamics TSD-OBD2273).

[0135] Of the six FIP1L1-PDGFRA 3C sequence orientations identified, two recurred (Table 1). Specifically, we identified the genomic sequence tagged GBA461GB_GBA496A6 four times. We identified the genomic sequence FH147946_FH149AA7 twice. Using single-step PCR, we amplified these six interactions in the AML cell line EOL-1. The FIP1L1 PDGFRA 3C B7 interaction was reproducibly found in the AML cell line (acute myeloid eosinophilic leukemia) EOL-1 (n=2, hydrolysis probe assay) using single-step PCR. The loss of topological shielding between FIP1L1 and PDGFRA in EOL-1 may be partially mediated by deletions.

[0136] The 462 base pair B7 interaction was amplified in two imatinib-sensitive cell lines: GDM-1 (n=1) and HL-60 (n=2). Both cell lines respond to imatinib, although the mechanism of topological shielding loss between the FIP1L1 and PDGFRA genes is unknown. The glioblastoma cell lines DBTRG-05MG (n=2 qPCR assays) and U-373 (n=1 qPCR assay) are also positive for the B7 interaction. The maximum copy number found in DBTRG-05MG was 29.89 copies (20 ng template, Table 2). One glioma sample with no identified IDH1 mutation or SNP rsll554137 had 1.19 (per 20 ng) of FIPL1-PDGFRA 3C fragment. Two glioma samples with identified IDH1 R132H mutation were positive for the FIPL1-PDGFRA 3C fragment.

[0137] qPCR standard curve (10 6 -1 copy) was generated from the sequenced PCR products. Analysis of qPCR data was performed using CFX Manager software (BioRad). Normalization was performed using stable 3C interactions in MMP1. Standard curves showed selective amplification of B7 interactions in AML and glioblastoma samples using single-step qPCR.

[0138] Using chromosome conformation, we successfully detected DNA sequences associated with loss of insulator function between FLIPL1 and PDGFRA in glioblastoma and AML-cell lines. Loss of shielding between FIP1L1 and PDGFRA genes leads to 3C alterations that are detectable in AML and glioblastoma using qPCR. These interactions cannot be detected using conventional sequencing methods.

[0139] Example 2. Development of a quantitative PCR assay To comply with the data and technical requirements for qPCR addressed in the MIQE guidelines, we developed a novel technique for the amplification and detection of 3C using qPCR. Quantitative real-time PCR (qPCR) allows the determination of DNA copy number with high sensitivity in targeted samples. It proved to be particularly suitable for the demanding analysis of nucleic acid products related to the detection of chromosomal interactions.

[0140] The MIQE guidelines provide specifications for the minimum information that must be reported for qPCR experiments to ensure their relevance, accuracy, correct interpretation, and reproducibility. MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) is modeled on similar guidelines created for DNA microarray analyses, proteomics experiments, genomic sequence specifications, and under discussion for RNA interference studies and metabolomics, all of which are initiatives coordinated under the umbrella of MIBBI (Minimum Information for Biological and Biomedical Investigations).

[0141] Traditionally, in 3C analysis, when a fluorescence-based PCR approach is used, 3C fragments are designed in a predefined "constant" region of the complex DNA. However, such approaches do not adhere to the MIQE principle of qPCR and are technically a derivative of nested PCR. Such approaches require that at least half of the interactions are known.

[0142] In conventional detection techniques, DNA polymerase cleaves only the probe that hybridizes to the known DNA target and the inverse PCR primer if it binds to the same 3C library fragment. An increase in fluorescence occurs only if the target is complementary to the probe and is amplified during PCR. Because of these requirements, non-specific amplification is not detected.

[0143] From the amount of genomic DNA required to detect ligation products, it is estimated that a locus-specific ligation event can occur in only 1 / 2,000–1 / 20,000 mammalian cells. Therefore, reliable quantification of ligation products using conventional approaches is only possible if large amounts of DNA (i.e., many genome equivalents) are added to each PCR in conventional techniques. However, we were able to achieve quantification using only 20–100 ng of 3C template (approximately 3.2 × l0 ng) per PCR with our novel technique. 4 ~1.6×10 5 We routinely use 3C hydrolyzable probes (genome equivalents) to bind across ligation junctions. This also requires that microarray analysis be compatible with PCR analysis.

[0144] Why do existing technologies not work using conventional techniques? Technical issues related to the specificity of 3C copy number detection and quantification. The traditional approach requires two sets of primers, and two rounds of PCR. Technically, it is a derivative of nested PCR with fluorescence-based detection. Other approaches mimic this, but with one primer set and for 45 cycles of PCR. Although differences between samples can be seen, the approach is not quantitative and contains a number of significant technical problems: (a) Nested PCR is accepted as non-quantitative and does not allow accurate and precise quantification of low copy numbers due to differences in the efficiency between primer sets and PCR reaching the plateau phase in a given reaction. (b) Non-specific products can be amplified using nested primers. (c) Assays are often not sequenced. (d) Although the two-round PCR approach is not "authentic," absolute quantification of copy number can be obtained from the data. (e) No standard curve is generated (requiring one round of PCR), making accurate and precise quantification of low copy numbers impossible. (f) Existing kits have been established for safe clinical qPCR assays but are not compatible with Induction Line. (g) TaqMan PCR often amplifies multiple PCR products, raising significant technical issues regarding product specificity. (h) Point (g) Regarding the use of a hydrolysis probe for the detection of 3C, the probe is located in the "constant region". (i) The constant region is not a sequence-specific region for either the 3C fragment or the TaqI site - any specificity claim that the PCR product detected by the hydrolysis probe is a 3C fragment is therefore questionable.

[0145] The traditional approach uses the following controls: Control 1. Create a control template that contains equal amounts of all ligation products. Use this template to normalize for differences in primer efficiency.

[0146] Control 2. Determine interactions between separated sites by increasing genomic distance to estimate the frequency of random interactions. A good starting point is to test approximately a dozen interactions between sites separated by genomic distances ranging from 0 to 100 kb.

[0147] Control 3. When comparing two different cell types or two different conditions, determine interactions in genomic regions that are predicted to have similar conformations in the two cases. Use this data set for normalization so that data from the regions of interest can be quantitatively compared.

[0148] A specific interaction is detected if, after normalization for primer efficiency (Control 1), a local peak in interaction frequency is observed (Control 2). Analysis of unrelated genomic regions (Control 3) can then be used to compare different cells or cell states to establish whether a specific interaction correlates with biological activity such as transcription of the locus.

[0149] However, the technique we developed does not require such controls to be in place. Specific amplification and detection are achieved due to the selection of primer and probe binding targets combined with the use of a fluorescent quencher labeling system. For example, Table 3 lists some suitable fluorescent probes and quenchers.

[0150] Example 3. Characteristics of target sequences EpiSwitch™ qPCR technology uniquely utilizes targets that span the TaqI restriction sites in the ligated juxtaposed DNA fragments for hydrolysis probe detection (Table 4). Usually, the sites selected for detection using hydrolysis probes are selected for their efficiency of hybridization to the probe, and their tendency to form secondary structures and other biophysical properties that may interfere with the probe hybridization process, such as folding and bending properties and lowest free energy levels. This explains why any use of hydrolysis probes in the context of 3C detection so far has targeted the probe within a portion of the ligated fragment and not overlapped with both. This strongly weakens the specificity of detection of only the ligated product against all ligated and unligated fragments within the target sequence.

[0151] DNA curvature and the lowest free energy level at the ligated juxtaposition of Check Point Charlie (CC) sites around a TaqI restriction site indicate secondary structure conformations that distinguish conventional targeting sequences for hydrolysis probe hybridization. Probes are designed on the juxtaposed TaqI fragments spanning the restriction sites. DNA curvature is determined by the BEND algorithm. 1 The curvature is calculated by summing the roll, tilt and twist angles of the dinucleotide geometry according to Zuker. Curvature is expressed as degrees per helical turn, e.g., 10.5° per helical turn or 1° per base pair. The minimum free energy ΔG at a TaqI restriction site is calculated according to Zuker. 2 The algorithm calculates the nearest neighbor energy parameters 3 The calculation is performed by estimating the energy minimization using

[0152] In EpiSwitch™ technology, we scan up to 400 base pairs of upstream and downstream sequences from the TaqI site and calculate the DNA curvature. As a result of ligating together two CCs with high secondary structure, the sequence targeted to the ligation site shows a quantitative difference in curvature propensity compared to conventional target sequences for hydrolysis probe hybridization. The technology looks for a curvature propensity peak score above >5° per helical turn. Values ​​below 5° per helical turn compared to valleys of neighboring sequences may indicate that the DNA may adopt a curved conformation.

[0153] We also scanned up to 20 bases of sequence upstream and downstream of the TaqI restriction site and performed oligo correction as described in the Zuker algorithm with 0 mM NaCl. + and 4.5 mM Mg ++ The minimum free energy ΔG of linear DNA is calculated at 60° C. in the ionic state of 1. Sequences having a thermodynamic structure with a free energy level of less than 1.15 kcal / mol at 60° C. are selected for probe design.

[0154] Such sequences present in regulatory regions of genes such as promoters, introns, and terminators exhibit secondary structure conformations that are identified by the EpiSwitch™ platform by calculating curvature and free energy values. Probes were designed to span TaqI restriction sites on the sequences selected with the above curvature propensity and lowest free energy levels.

[0155] Conventional use of hydrolysis probes does not utilize such biophysically constrained sequences at the ligated junctions of CC sites for targeted hybridization, but in the context of EpiSwitch processing and detection, we are able to use hydrolysis probes specifically for the TaqI ligation site overlap with all qPCR controls, showing efficient and proportional detection of ligated products by copy number relative to nonspecific controls. This is the first practical use of hydrolysis probes targeting 3C overlaps performed in the context of an EpiSwitch assay, designed based on a temperature gradient study for scheduled and effective probe detection.

[0156] The methodology is illustrated in the following examples: Array 1 TTCCACGTGGCCTACCACAGCATGTCAGGCCTGGGGGCAGAATCTTGCCATACTGTGCAGCCCAAATTTGAATGCCAAAGGCTTTCGTTTGTCTCTGGGGGGCCACAGTCTAGGTCTAGTTCTGT GCAGGAGTTGTAATATTTGCTCTTCTCTCCCTCCTCCAGCTCGCAGACCTCTGAAGAGAGTGCCATTGAGACGGGTTCCAGCAGTTCCACCTTCATCAAGAGAGAGGACGAGACCATTGAAGACA TCGAAAAGATAAAACAGGTGTTAGTGAGGATATGGGAAATAAAACCCTCATACACTTCTGGTGGGATTGTAAAATGGTGCAGCTGCTTTGAAGAACAGCCTGGCCATTTTCTCAAATGGTGAAACATGGAGTTACCATGTGAGTCCTCCCCTTAGAGGAATGAAAACATATTCAGACAAAAACTTGTACGTGAATATTCATAGCAGCATTATTCTTAATAGAAAGTGGAAAAAGAAAACCTCGCAGCTG

[0157] The curvature propensity profile of the sequence is plotted below. Here, the profile shows a curvature propensity magnitude of over 5° for 50-100 bases, followed by a valley of low scores. This indicates a curvature conformation of the DNA. DNA folding and free energy estimation of the sequence surrounding the TaqI region reveals that the DNA conformation is highly conformational at 60°C and 4.5 mM Mg ++ The lowest thermodynamic structural free energy ΔG of 1.13 kcal / mol was obtained in the ionic state. This region corresponds to an intron region of FIP1L1 and the 3' end of the PDGFRA gene, and represents a highly regulated region. This aligned TaqI fragment was selected and a probe was designed spanning the restriction site. The TaqI restriction site in the sequence is shown in white against a black background.

[0158] Array 2 TGGGAGTGGGTGGAGTGAGAACCTGGGAGAAGGCCAGCCCTTTATATCCAGGCAGACAGCTCCAAGTGCCACCATGGATCAGCCAGTCTTGCAGGGGTGATGCTATTCAGCTACAGATGGCTTGATCCTGAGTCATTTCTTCCTTTTCCATGCAGTGTGTC CACCGTGATCTGGCTGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCTGTGACTTTGGCCTGGCCAGAGACATCATGCATGATTCGAAAAGATAAAACAGGTGTTAGTGAGGATATGGGGAAATAAAACCCTCATACACTTCTGGTGGGATT GTAAAATGGTGCAGCTGCTTTGAAGAACAGCCTGGCCATTTTCTCAAATGGTGAAACATGGAGTTACCATGTGAGTCCTCCACCTTAGAGGAATGAAAACATATTCAGACAAAAACTTGTACGTGAATATTCATAGCAGCATTATTCTTAATAGAAAGTGGA AAAAGAAAACCTCGCAGCTGCATCAACTGATGAATGGATAGATTAAATGTGTTATATCCATACAGCGGAATATTATTTGGCAAGGACAATAAAATGAAGTACTGGTAGATGTTACAACACGGATGAACCTTACAAATGTGGAAGCTAAAGATGTCAGTCGT

[0159] Scanning of the 647 bp sequence around the TaqI of the two aligned fragments shows a magnitude of curvature tendency above 5° per helical turn at approximately 210 bp surrounding the low-scoring valley. DNA folding and free energy estimation of the 44 bp sequence surrounding the TaqI region was performed at 60 °C, 4.5 mM Mg ++ The lowest thermodynamic structural free energy ΔG of 0.78 kcal / mol was obtained for the ionic state.

[0160] Array 3 GCAGCTGCGAGGTTTTCTTTTTCCACTTTCTATTAAGAATAATGCTGCTATGAATATTCACGTACAAGTTTTTGTCTGAATATGTTTTCATTCCTCTAAGGTGGAGGACTCACATGGTAACTCCATGTTTCACCATTTGAGAAAATGGCCAGGCTGTTCTTCAAAGCAGCTGCACCATTTTACAATCCCACCAGAAGTGTATGAGGGTTTTATTTCCCCATATCCTCACTA ACACCTGTTTTATCTTTTCGAGGTCCTTGCTGAACCTGGACCTATAAATGACGTCAATGATAGTGATCCTACTGCAGAAATCTACAAGTGGCTATAAAGAACTCTGTAGGTAAGAAATTCTGTAAGATCAGAAAGTACAATGAATTCACTTCATAATAAATTACTTGGTGGACACCAAATGGGTGCTAAATTGATTGGGTAGAAGGAATTGTATGCCCAAGCCACATGGC

[0161] A scan of 462 bp of sequence spanning upstream and downstream of the TaqI restriction site showed a magnitude of tendency greater than 5° per helical turn between approximately 400 and 450 bp, and values ​​for the surrounding sequence less than 5° per helical turn. DNA folding and free energy estimation of a 44 bp sequence surrounding the TaqI region revealed that the fold-folding and free energy estimation of the fold-folding and free energy estimation of the TaqI region at 60°C and 4.5 mM Mg ++ The lowest thermodynamic structural free energy ΔG of −0.93 kcal / mol was obtained for the ionic state.

[0162] Array 4 AGTACTTCCTTCCCCTCCCATATTGTTAAAAATAGTTTACATTGCTTCCCAGGCTGGGCTGGTGGAGTTGGCACGAGATGTCAGAGGAACCTGAGTCATGCTCAGGCCCAAGCCCTGTTGGCA GGCAGACCACTGCTTTCTGGCCTTCCGTGACTATCTGAAAAAAATCGTGAATGGCTAGAGCTACTCTTCACTTGCTGAACATTTTCAAAAAGAATTGAGAACTTCTGGATTAAATTGCCTTCTTC CTCGAAAAGATAAAACAGGTGTTAGTGAGGATATGGGAAATAAAACCCTCATACACTTCTGGTGGGATTGTAAAATGGTGCAGCTGCTTTGAAGAACAGCCTGGCCATTTTCTCAAATGGTGAAACATGGAGTTACCATGTGAGTCCTCCCCTTAGAGGAATGAAAACATATTCAGACAAAAACTTGTACGTGAATATTCATAGCAGCATTATTCTTAATAGAAAGTGGAAAAAGAAAACCTCGCAGC

[0163] Scanning of the 499 bp sequence spanning both upstream and downstream of the TaqI restriction site revealed two curvature trend peaks at approximately 160 and 240 bp. DNA folding and free energy estimation of the 44 bp sequence surrounding the TaqI region at 60 °C and 4.5 mM Mg ++ The lowest thermodynamic structural free energy ΔG of 1.14 kcal / mol was obtained for the ionic state.

[0164] Array 5 CCTCTCCCACACAAACCTGCTACTGAGTACCTTCGCTAACTTAACCATTCATTCACCCTGGAAGACCACCTACTAGCAGAAGGATTCTTAACAAATGTAAAGAAAGTAAGGACTTTACACTAACAATACAAAACTAACTCTCTCTTTGACAA TTCAAAAAACAAAAGATGTTGAACTTTGACATTTACAGAATTAAATGTCAAATGTGACACAATACCATCACATCTGGCTAACTAACTCTTATGCTTTTTTTAGTAAGGAACAACTTTTGAGCCTCAATATCTTAATTCTTAAAATGATAAAG AACACTTAACTCAATTTGTTGAGATCAAATAAGGTAATGTAAAAGTGGGATTTTTATTTTTACTTATTTATTCGAAAACCCTGGGACCCTTCCAGATGGGACTAACTGGGGAAAGTGGACAAGTTACAAACAAAGAAACTCAAAGGAAAGTC ATTGGCACTGATCTCTAAGATGCTATCACATGTGATTGGTGGTTGATTTTATTAACAAATTATAAGCAAAGTACTACAAAGGTGGCTTTAAAAAGAAAATAAAGCAATTCACAGAAACTACTTTTTCATGTAGCTTGTATGTGTGCTCCATGT

[0165] Scanning of the 609 bp sequence spanning both upstream and downstream of the TaqI restriction site revealed two curvature trend peaks at approximately 200 and 500 bp, as well as a low-scoring valley. DNA folding and free energy estimation of the 44 bp sequence surrounding the TaqI region revealed that the DNA folding and free energy were significantly reduced at 60°C and 4.5 mM Mg ++ The lowest thermodynamic structural free energy ΔG of 0.51 kcal / mol was obtained for the ionic state.

[0166] Array 6 AAATGATGAGGCACGGGTGAATAAGATAGTTGGAAGTGACACATACAGATTTCAAATAATTCCCTAAAGGTGTATGGTTTTCTTTCCCTACAAATCCTACTTTCAGTTCTTTTGTACATGGACCCAGAGTGGAATTGCTGGATCAT ATGATAATTCTATTTTTAACTTCTTGATGGACCTCTGTTTTTGTTTTGTTTTTTACAGAGGCTGCAACATTTTATATTCCTACTAATAATGCACAGGGGTTCGGATTTCTCCACATCCTTGCCAACACTTGATATTTCCTGGGTTTT TTGATAATGGCCATCCTAATAGGTGTGGGGACATGAGGTTTTCAATATGCTTGTGGACATCGAAAACCCTGGGACCCTTCCAGATGGGACTAACTGGGGAAAGTGGACAAGTTACAAACAAAGAAAACTCAAAGGAAAGTCATTGG CACTGATCTCTAAGATGCTATCACATGTGATTGGTGGTTGATTTTATTAACAAATTATAAGCAAAGTACTACAAAGGTGGCTTTAAAAAGAAAATAAAGCAATTCACAGAAACTACTTTTTCATGTAGCTTGTATGTGTGCTCCATG

[0167] Scanning of the 586 bp sequence spanning both upstream and downstream of the TaqI restriction site revealed two curvature trend peaks and a low-scoring valley at approximately 300 and 500 bp. DNA folding and free energy estimation of the 44 bp sequence surrounding the TaqI region revealed that the fold change was consistent with the fold change observed in the TaqI region at 60 °C and 4.5 mM Mg. ++ The lowest thermodynamic structural free energy ΔG of 0.51 kcal / mol was obtained for the ionic state.

[0168] References: 1. Goodsell, DSand Dickerson, RE (1994) “Bending and curvature calculations in B-DNA” Nuc. Acids Res. 22, 5497-5503 2.Zuker (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nuc.Acids Res.31,3406-3415 3.SantaLucia,Jr(1998)A unified view of polymer, dumbbell and oligonucleotide DNA nearest-neighbor thermodynamics.Proc.Natl.Acad.Sci.USA 95,1460-1465

[0169] TIFF0007579003000001.tif254170

[0170] TIFF0007579003000002.tif254170

[0171] TIFF0007579003000003.tif254170

[0172] TIFF0007579003000004.tif254170

[0173] TIFF0007579003000005.tif170170

[0174] TIFF0007579003000006.tif254170

[0175] Example 4 Further studies Detection of aberrant tyrosine kinase activation is currently unsuccessful with conventional diagnostic methods (e.g., sequencing) in multiple indications. Tyrosine kinase inhibitors, such as dasatinib, imatinib and ibrutinib / imbruvica (Janssen-Cilag Ltd), are being developed for many malignancies (chronic) and constitutional disorders. Examples of potential non-malignant indications for Bruton's tyrosine kinase (BTK) inhibitors include arthritis.

[0176] Clinicians require evidence of molecular damage in the target tyrosine kinase prior to prescribing a tyrosine kinase inhibitor. Potentially life-saving therapeutic interventions using tyrosine kinase inhibitors (TKIs) would be unsuccessful using conventional diagnostic methods.

[0177] Medication-Related Aspects of the Invention: (a) Imatinib therapeutically targets the 3C conformation:

[0178] We demonstrate that the ATP-mimetic imatinib, known to act directly against activated tyrosine kinases, also acts directly against the 3C chromosome conformation in imatinib-responsive genes such as cKIT. (b) GSK therapeutically targets the 3C conformation:

[0179] For the IDH1 inhibitor GSK864, we present data showing that the drug directly inhibits chromosome conformation in multiple cell lines. Stratification of cancer patients for effective treatment was performed by identifying activating mutations in tyrosine kinase genes and acquired alterations in other pathways. Diagnostic procedures that help to stratify patients in this way are of potential great benefit. Conformational changes to FIP1L1 and PDGFRA enhancer regions upregulate PDGFRA expression in glioma patients with IDH1 R132H mutations. Ectopic PDGFRA overexpression is treatable with imatinib.

[0180] The following data relates to 3C markers and their use in functional qPCR assays: ABL1 and cKIT show dual differences between non-malignant samples and cell lines.

[0181] RC = reverse total complement. The authentic reverse primer sequence is adjacent to the RC sequence.

[0182] Genes with identified 3C interactions and the indications they are involved in: 1. ABL1, a cytoplasmic tyrosine kinase gene located at 9q34: Indications: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), breast cancer. chronic myeloid leukemia (CML) and CML-blast crisis or gastrointestinal stromal tumors (GIST). myelodysplastic syndromes (MDS) or myeloproliferative disorders (myeloproliferative neoplasms, MPN). 2. Bruton's tyrosine kinase, a cytoplasmic tyrosine kinase gene located at Xq22.1: Indications: X-linked agammaglobulinemia (XLA), B-cell malignancies. NHL, lymphoma (all types), myeloma. Chronic lymphocytic leukemia. Patients with recurrent mature B-cell neoplasms. Chronic graft-versus-host disease. Recurrent hairy cell leukemia. Recurrent or refractory solid tumors. Refractory mantle cell lymphoma. Amplified esophagogastric cancer and rheumatoid arthritis. 3. cKIT, a receptor tyrosine kinase gene located at 4q12 Indications: Mastocytosis and mast cell leukemia and prostate tumors. Advanced melanoma, mutated malignant melanoma, secondary, unresectable or metastatic gastrointestinal stromal tumor (GIST), manifested malignant mesothelioma. Advanced, platinum-refractory ovarian cancer. Recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer, or ovarian low malignant potential tumors. Patients with uterine papillary serous carcinoma, advanced stage small cell lung cancer, locally advanced nasopharyngeal carcinoma, recurrent / refractory non-Hodgkin's lymphoma. Metastatic renal cell carcinoma, metastatic gastrointestinal pancreatic neuroendocrine tumors, recurrent ovarian clear cell carcinoma, esophageal squamous cell carcinoma, persistent uterine and breast cancer. 4. FGFR1, a receptor tyrosine kinase gene located at 8pll: Indications: thyroid cancer, oral adenoma, chronic leukemia, acute leukemia, prostate tumors and breast cancer. Recurrent head and neck cancer with translocation, mutation, or amplification of FGFR1-3. Recurrent malignant glioma expressing FGFR-TACC gene fusion. Patients with advanced non-small cell lung cancer. 5. FIP1L1, polyadenylation specificity factor (4q12) frequently fused to PDGFRA. Non-tyrosine kinase gene: iHES, chronic leukemia. 6. FLT3 receptor tyrosine kinase gene located at 13q11-12.2: Indications: chronic leukemia, acute myeloid leukemia and breast cancer, iHES, chronic leukemia. Non-small cell lung cancer (NSCLC). Colorectal cancer, metastatic melanoma or renal cell carcinoma, glioma, refractory Hodgkin's lymphoma. Previously treated ovarian cancer. Locally advanced nasopharyngeal carcinoma. Refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL). Sumitinib-failed gastrointestinal stromal tumor (GIST). 7. PDGFRA Receptor tyrosine kinase gene located at 4q12: Indications: glioma. chronic leukemia, acute myeloid leukemia and breast cancer, iHES, chronic leukemia.

[0183] TIFF0007579003000007.tif146170>ORF1_9_130700600_130703071_130719461_130720884_FR GCAAGCTCCACCTCCTGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGTGTGCCCCACCATGCTCTGCTAATTTATCTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGTCAGGCTGGTCTTGAATTCCTGACCTTGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGA CATGAGACACTGCACCCTGCCCCATTCCTTTTAATCTCCCTTGGAATTAGCTGTTTGGTTGATTTGGAGTTCCAGGGTGATACTGTCTGAGTCATAAATGATTTATTTGTGAATTTCTGTGGCTGGTCACGTATTTTGGTCCTGTTTGTATTTCCCTTCCCCTCTCTGTGTCTCCTTAGCCTGTCTCTCTTGCTGATC GAGGTTGCAACGAGCTGAGATTGCACGCCACTGCACTCCCAGCCTGGGCGACGGAGTGAGACTCCATCTCANNNNNNNNNNNNNNNNNNNNNNNNNNNNNTGATGACAGCCCAACCTGTCACTTTTTCAGATCCCTTTTTATGAAAGAATTTGCTTAAGTTGTGTCTGAAGACAAACCAATTTCTTTGGACCCTG GGTATTCTTTTTCTAAGGGAATACCATGTTATTTTGTGTTACAGATTGTTTGCGATCTTTCATAGGCTGATCTTTCTAGAGTTGGTTAATATCCATGTAGGTTAGATTGAAAAACTTGAATTCAGAAATGTACGGTGTTGGAGCAGACATGGATCTGGAAGCCAAGAATAGCGTTGGTGTTGTTGTTGATGGTGAATCTG

[0184] Lab Chip data show amplification of 3C interactions in normal material (patient 375) but not in chronic myeloid leukemia blast crisis cell line K562 (68° C. primer annealing temperature). This pattern was also seen at annealing temperatures of 67.5° C. and 66.4° C. Expected product size: 515 bp.

[0185] TIFF0007579003000008.tif150170

[0186] >ORF1_9_130700600_130703071_130719461_130720884_RF CCACTGCACCAGAGCAAAGAGCAAAAGGAGAGATGCAGGAGGTAAAATGGAGGGTGGGAAGAGAATGGCTGAAGGAGAGGGTGGCCTTATTGGCCCATTTCAAGGATTTTGACTTTGATTCATATGATGTGGGAAGGCCTTGGAGAATTTTCCGAGGGGACTATACTATCTGATGTATGTTTCAGTATGAAATAGAATCTCTCTGGCTGCTATGATCTGAAGGAGGACAAGGGAGCAGGGATTCCACGGGGGCATTGATTGCACAGAGCCAGGTAAGAGTGATGATGCTTGGACCAAAGTGGTGGCACTGGGTGGAGGGTCAGAACCGACAAGATTTGCTCTCGGATTAGATGTGGGATATGGGGGTGTGAGAGGGGCCAAGTGTGACTCTCAGGTTTTCGACCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGCACCTGGCCTTCTGTCTGTATTTTTAAAAAAAAGATATTCATGACAACCAAGGGGAGAGGTAAGGTCACAGTGATGTGCTCTGGGTCAAAGATTGTTGAGCCTGGACCATTGGAGAGGGGAGGAAAAGATGGAGGTGTGGGGTCAAGGGGAGAGGCTGCAGAGGACAGGACAGTGTGTGGCCAAGGCTGCTGTTTGTTCCTTCATCACCCTGGCCAGGCTGAGGTCCAGGCAGTGTTCTCTGACGGAGCTGTCTCTTTGCACACGAGGAGCCTGAAATATGGAAAAGTAAGTCGGGCTCTTGATGTTCCTGTTTGCTGACTGAGACTACAAGGCTATTTTTGAATCCCCAT

[0187] Lab Chip data show amplification of the 3C interaction in normal material (patient 375) but not in malignant material (from cell line K562) at 67.5° C. Expected product size: 676 bp.

[0188] TIFF0007579003000009.tif194170

[0189] B-cell malignant tumors = malignant tumors thought to contain Bruton's tyrosine kinase

[0190] >ORF2_X_101355470_101357976_101407183_101408846_FR ATGAGTCCTGAAACAGAGAGAGAGGTCATGCTGTTGGTGTGGTGTAGGAGGTGGGATGCC TCACACATCCTCACTTAAAGCCTCACACTTCCGGTGTGTATCTTTCTAGTACATTTTGAA TCCCAGAAGACCTCCATGAACCCACATATTTCCAGAGGTTTCTCCTTCTCACAAAATACTT TTCAGGGACAAAAAAGAGAAAATACTAATTGAAATACACTGCCTAACTGAATATATTCCC ACCTCCCAGCCCAGGCTTAGCTCACATCCTACCTTCTTGATGAAGCTGTTCCCCCATATC CATGCCCTCACTAATGTCTCAGTTTTTAGAAATTTTACAGTGCTTATAAACTTTCTTCTG ATGTTGTCTAACCTGTATGTTCTTTGAGGACAAGGACCTCGAGATACTGCCGAGAAATCC ACGACCCCAAAAGGAGAAAAAATGGCACGAATCTTAGTTCCCCATTCCTCCTACCCACCC TAGATGTTCTAACGGTTAGCACCCGGCAGAGGAAGAGCAGAAGTTCACAAGAAGGGTCTG

[0191] Lab Chip data shows amplification of 3C interactions in cell lines only at this annealing temperature. Expected product size: 155 bp.

[0192] TIFF0007579003000010.tif196170*Note that these primer combinations produce single step products and were not used for nested PCR.

[0193] 1>ORF3_4_54711719_54715167_54736749_54740853_FR TCCCATTTTGAAAGCTTATCCTTTAATGACGAGCTTCAGCCAGTGCGGTGGGAGTACTGT GATCCTCACGTGGTGGTGACGGGGAGGCAGACATTGAGAACTGAAGGGCTCCCTTTGATC ATTAGCCTTACATAGGATGCCTTTAATGTTGAGCTAGATTGGAAGCCCAAGTGACTGCTG AAGTGCACCAATTAACTCAGAAGTCACCAATTTCACTCCATTTATGGAAGGGTATTAAC AGGGGGTTGAGAAACAATTTAAGGAAATGTTAAATAATGTATTATTTCCAAATCACTGCA TCATATAATTAACATCCTACCTGTTGTTAGCAATTATTTATAGGTCATACAGTATACCAA AATCAGCCAAAGCAATAAATCACCCAGAATAAGGCTTCTCGATTCTAAGTTCTACAAGAT GATCAAGGAAGGCTTCCGGATGCTCAGCCCTGAACACGCACCTGCTGAAATGTAAGAGCC AAAAAATTTTTCCTTTAGGTCACGTTTTCCCTTTTATTTTTCTTTTTAGAGACAGAAACC CAGATGTTGAGGGTTTTCATAACACAGTTTGAAATGTCACTTGGATTCTTTATGACACAC TGGTCAAATGTCATTTCTGTAGTTTATTTTCATAATCTCTTGTCACCAAAAATACAGAAA GTTTCAGTAATATTTCATACATGCAGTGTTTTATGTTATCTATATGTCAGTCCATATGTC CAGTTGCATAGCCCTGGAATTATTACTGAAGTTGCTGGATGCCCATACATTTGAAAACAA GCTGAGGGCATTGAGGAGG

[0194] Lab Chip data show amplification of the 3C interaction in normal but not malignant material (from cell line EOL1). The expected product size is 429 bp.

[0195] TIFF0007579003000011.tif166170

[0196] >ORF4_8_38427499_38430449_38480545_38486034_FF(5) GAGCCGCACCATCCTGGGCATCACTTACTGGAGGCTACTGAGCCAGGCAGTGGGAATTGGAGCATGGGTCAGTGGGGAAAACAGCTGGCTGCCTGGGAACCCCCATCTCTTTCCACCCCACTCCTCCAAAAGTCAAAGGAAGAAAGAGGCAAAGTTAGGAAGCAGCTGTAGCAGCATTAAGCGCATTTCATTTCCCCC ATCCTAAGGGAAAGGTCGGCCCTCCCCAGGACTTCTTTGTGTCCGGAGTTGCCCCCTCCCCAGATGCTCAGTTCTTTGCCAAGATTGCCACTTGCCAGAGGAACACCCCATTTCCTTTGGGATAGCTCAGCCTCACCCTTCCCTAGCAACAGCTGAACAAACCCCGCCCCTCAAACCCCAGCAGCCCCTGCCCAAGTC GAGGGAGCAGCTCCCCACCCAGCCCCAGGATCTGGGTCCAGCAGACCTGGAGAGTCTGCCCTGGCTGCACAGACCGTGGTGGGACTGTCTGGCGGAACTGTTGTCTGGACAATGCAGCCCATGTGACAGGCCTTAATGAGTCCCTTCTGGAATCCCACAATGGCCAAGTGGCACAGGCTCTCTGAATAGGTTGCTGTT TTTCAGCAGTGGCAGGGGCTGTGTTGTGGCAACCTCCTCTCTTATTCAACCTCCGGCATCTCTCTTCTTTTCCTTTCTTTCTTACCTTTGTCTTTTATCTACTTTAACTCTCCTGTTCCCTTTTGATCTCTTCCTTCTCCTCCACCCTCCTGATTTCTGTTGTTTCTTAGACACAAAATCGCCCTTCACTCCTGCCCTGT

[0197] Lab Chip data show amplification of the 3C interaction in normal material (patient 375) but not in malignant material (cell line CCL30) at 68° C. Expected product size: 460 bp.

[0198] TIFF0007579003000012.tif225170

[0199] >FIP1L1PDGFRA_4_54231931_54236063_55143356_55145047_FR CAGCTAAAGACTACTTTTCCAAGCCTCTTGCAGCTAGCTATGGACAAATGATGAGGCACG GGTGAATAAGATAGTTGGAAGTGACACATACAGATTTCAAATAATTCCCTAAAGGTGTAT GGTTTTCTTTCCCTACAAATCCTACTTTCAGTTCTTTTGTACATGGACCCAGAGTGGAAT TGCTGGATCATATGATAATTCTATTTTTAACTTCTTGATGGACCTCTGTTTTTGTTTTGT TTTTTACAGAGGCTGCAACATTTTATATTCCTACTAATAATGCACAGGGGTTCGGATTTC TCCACATCCTTGCCAACACTTGATATTTCCTGGGTTTTTTGATAATGGCCATCCTAATAG GTGTGGGGACATGAGGTTTTCAATATGCTTGTGGGACATCGACAAAAGCAATTATGCTAA TTTCCTTCCCTGTGGGCTCAATTCCTTTTTTGACACGATGACTTGGAGGAGTCATTATGA TTACTCCAAACAGGAAAGACACTCGCCCAGCTGTCCGCCCGCAGAGAGCTGGCTACGGTG CAGAAAGCTGAGGAGGCGTCTGGAGTTTTTGGGTGTTAATGATTCTGCCTGCCCACAGGT CGGGTCTTGGGGTCTGGAGCGTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGC CGGTCCCAACCTGTCATGAAAGTTGCAGTGAAGATGCTAAAACGTAAGTGCTCCTTCCTG GGGATTTTTTGAGCACGGGGATTTTTTGAGCATGGGGATATTAAGGGAATTTCTCAAAAT CATGCAGCTAGTAAATAAGA

[0200] TIFF0007579003000013.tif158170

[0201] >ORF5_13_28025286_28026644_28116701_28118054_RF TAATTGCATCACTGCACTCCAGCCTGGGCAACAGTGAGAGAACTTGTCTTAAAGAAACAAAGCAGGTTCTTTCCTCTCAGAAGCCCCTCTCTCTTACTAGAGAGAGAGCTGTTCTCCTCTCTTTCTTCTATTAAACCTCCGCTCCTAAAAACACANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCCCTAAAAAA ACTAGCCTGGGCAACATGGTAAAACCCTGTCTCTACAAAAAACACAAATAAACTAGCCAGGCCTGGTGGTATGTGCCTGTAGTCCCAACTATTCAGGGAAGCTGAGGTGGGAGGTTTGCTTGAGACCGGGAAGTCCAGGCTGCAGTGAGCCGAGATGGCGCCACTGCACTCTAGCCTCGGCGACAGAGTGAGACTCTGTC GATCTCATTCTTTGGTTTCTGAACTCAGCCCACTTTCCCTCACATAATACAGATCTTTCCCGAGAGTCCCGTAAGCGTTTCACCATCCTTCTTTTTTCCAGTTTGCCTTTGTAAAGCTCATTTCTTTTACTGTGAAATTAATAAATAGCAATACAAATCTCTTTTAAGGTATAAAAATTCTTCCCTGAGGAGCTC TGTAGGAATTATAAGTAGATCACGATTCAATTTATTCTAATATACGAGTTTAACCCAATTTACAATTTACATATCTTTAGGAAATGGCTTCATGCTTTCAGACCACAAATATTCCAAAAGGAATAATTTCAGTGTATTTAATATTCCAGTGAACAGAACGAATCAAAGGGGCTAAGTACTGACCAGTGGATACTGGTCAC

[0202] Lab Chip data--row B. This shows amplification of the 3C interaction in normal material (patient 376) but not in malignant material (from AML patient 277) at 67.5° C. Expected product size: 223 bp.

[0203] TIFF0007579003000014.tif157170

[0204] No 3 >ORF5_13_28025286_28026644_28116701_28118054_FF NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNAAAGAATGCTCCAAGGCTCAACGAATGCCTCCATCAGAATGCCTGGGAATCCATTCAGAGAAAGGTGCTACAA AGCCATGATGCTCAAGTAATTAGCAAGAAAGTTCAAGGATGAGGAGGAGATCCAGCAAACTCCTACAGCCCTCATTTATGCCCGCTAAAGCAATAAATCCCTGCAGGACCAAGCATCTCTCAGGATCCCCATGGATGCGGAGGATAAACACAGAGCAGAGACAAGGTTACTGCTACTTTACTGTGTCCCCATCACGTGTC GACAGAGTCTCACTCTGTGCCCGAGGCTAGAGTGCAGTGGCGCCATCTCGGCTCACTGCAGCCTGACTTCCCGGTCTCCAAGCAAACCTCCACCTTCAGCTTCCTGAATAGTTGGGACTACAGGCACATACCACCAGGCCTGGCTAGTTTATTTGTGTTTTTTGTAGAGACAGGGTTTTACCATGTTGTCCCCAGGCTAGTTTTTTAGGGNN

[0205] Lab Chip data show amplification of the 3C interaction in normal material (patient 376) but not in malignant material (from AML patient 277) at 68.0° C. Expected product size: 204 bp.

[0206] TIFF0007579003000015.tif140170

[0207] >ORF5_13_28025286_28026644_28116701_28118054_RR GTGACCAGTATCCACTGGTCAGTACTTAGCCCTTGATTCGTTCTGTTCACTGGAATATTAAATACACTGAAATTATTCCTTTTGGAATATTTGTGGTCTGAAAGCATGAAGCCATTTCCTAAAGATATGTAAATTGTAAATTGGGTTAAACTCGTATATTAGAATAAATTGAATCGTGATCTACTTATAATTCCTACA GAGCTCCTCAGGGAAGAATTTTATATACCTTAAAAGAGATTTGTATTATTGCTATTTATTAATTTCACAGTAAAAAGAAATGAGCTTTACAAAGGCAAACTGGAAAAAAGAAGGATGGTGAAACGCTTACGGGACTCTCGGAAGATCTGTATTATGTGAGGGAAAGTGGGCTGAGTTCAGAAACCAAAGAATGAGATC GAGTGATTGCTAGGTGATGGACCTGTAGGGAGAGATCACTAGATGAGTTCAGGTGGTAAATAGAAAACTCCTGTTGGGGTGCAGTGAGAGATGAAGGTAGTGAAATGAAAGGATGGGGATCAATTTTATATGAGGGCTTTAATTTGAAATGGGAATTTGGTGATATTCTCAGAGCAGCACAAGTTTTCATGCCATGGAAA AGCAGCAGGAAAAATGTAAACCTTGCCAAATAACACGGGAAAGTCTCCAAGGGTGCCCAGTGACTTACTTGCCTATAAACAAAGCCATTCCTGAGCACTTCTGGCTATGAAATTTCAAAATACATGTTTTAGAGAATTTTACTGACACTTTTATGATTTTAGAGGATAATTTAGATTTCATAAATTTTGTTTCCTTCCCTT

[0208] Lab Chip data show amplification of the 3C interaction in normal material (patient 376) but not in malignant material (from AML patient 277) at 68.0° C. Expected product size: 173 bp.

[0209] TIFF0007579003000016.tif156170

[0210] >ORF5_13_28009061_28014204_28025286_28026644_FR CACACTCATGCTTCATAAGAAAGGGCTAGTGGCTTCTGGAGGCCAGGGATTATTTTTATTTAGTTTTATTTAGTTGTCTACTTCACTGCACTGAACTCTTAAGAGCTTTTAATTTATTAATCATTTGGCTGAAATCAGGAAAGGTGTTTTTTTTCCCTAAAAACATTTTTATCAATATGTCTTAGGGCAGGCAGAGGAGC TCATGCCCTGTGATCCCAGCACTTTGGGAGGCTGAGGTGGGGGAATCGCTTGAGCCCAGGAGTTCAAGACCAGCCTGGGCAATACAGTGATACCCTATTTCTACAAAAAATAAAAAACTTAGCCTGGCGTGGTGCTGCCCTCCCATGGTCCTAGCTACTTGGAAGGCCGTGGCTGGAGGATTGCTTGAGCTTGGGAGGTC GATCTCATTCTTTGGTTTCTGAACTCAGCCCACTTTCCCTCACATAATACAGATCTTCCCGAGAGTCCCGTAAGCGTTTCACCATCCTTCTTTTTTCCAGTTTGCCTTTGTAAAGCTCATTTCTTTTTACTGTGAAATTAATAAATAGCAATAATACAAATCTCTTTTAAGGTATATAAAAATTCTTCCCTGAGGAGCTCTGTAGGAATTATAAGTAGATCACGATTCAATTTATTCTAATATACGAGTTTAACCCAATTTACAATTTACATATCTTTAGGAAATGGCTTCATGCTTTCAGACCACAAATATTCCAAAAGGAATAATTTCAGTGTATTTAATATTCCAGTGAACAGAACGAATCAAAGGGGCTAAGTACTGACCAGTGGATACTGGTCAC

[0211] Lab Chip data show amplification of the 3C interaction in normal material (patient 376) but not in malignant material (from AML patient 277) at 68° C. Expected product size: 742 bp.

[0212] Additional Data Conformation of the temperature gradient data is presented below. Selected interactions for each gene are presented below in alphabetical order, with average copies of each interaction in 20ng (per reaction = 1 well per 96-well plate) included. 1. ABL1 ABL1-515 SYBR-based qPCR assay for material from K562 cell line and normal blood (10 ng / reaction) K562 shows a reduced mean copy number at 20 ng (12.36333, SD + / - 15.67294) compared to 33.24667 copies per 20 ng in normal blood, SD + / - 35.04153 (p=0.143245 T test). 2. Bruton's tyrosine kinase ORF2_X_101355470_101357976_101407183_101408846_FR The cell lines (BT142, EOL1 and HL60) show a reduced mean copy number (20.99338 SD+ / -43.413166) at 20 ng compared to 43.83277 SD+ / -72.808926 copies per 20 ng in normal blood (0.41426T test). 3. cKIT experiment: Highly significant difference ORF3_4_54711719_54715167_54736749_54740853_FR Malignant cell lines (BT142, EOL1 and HL60) show a reduced mean copy number at 20 ng (0.205135 SD + / - 0.453526) compared to 2.639932 copies per 20 ng (SD + / - 1.742175) in normal blood (p=0.001294 T test). This is a highly significant difference between the cell lines and the non-malignant samples. 4.FGFR1 ORF4_8_38427499_38430449_38480545_38486034_F The malignant cell line CCL30 shows an increased mean copy number of 2.05 (SD+ / -0.843267) at 20 ng compared to 1.242222 (SD+ / -1.715319) copies per 20 ng in normal blood (p=0.314743 T test). 5.FIP1L1 Experiments FIP1L1PDGFRA 4 54231931 54236063 55143356 55145047 FR Malignant cell lines (BT142, EOL1 and HL60) show a reduced mean copy number of 13.07325 (SD+ / -19.46042) at 20 ng compared to copies of 32.61117 (SD+ / -38.58252) at 20 ng in normal blood (p=0.147896 T test). 6.FLT3 experiment: ORF5_13_28009061_28014204_28025286_28026644_F: Significant difference Malignant patient material shows a reduced mean copy number of 0.427619 (SD+ / -0.667599) per 20 ng compared to 6.587778 copies, SD+ / -7.672794 per 20 ng in normal blood (p=0.043238 T test).

[0213] Drug Sensitivity and Imatinib Imatinib (Glivec) exhibits activity against multiple tyrosine kinases, including ABL1, cKIT and PDGFRA. Successful clinical trials in chronic myeloid leukemia have provided the impetus for the identification of pharmacogenetic strategies. Examples of novel data regarding the effect of imatinib on selected genes that are imatinib responsive are provided below: 20 ng of template was added to each well for samples treated with imatinib. The cKIT interaction (ORF3_4_54711719_54715167_54736749_54740853_FR) and Imatinib: cKIT and exemplary data. BT142 cells were treated with 1 μM imatinib. 20 ng of template was loaded into each well. Note that cKIT 3C interaction was completely absent in the imatinib-treated cell line (see below).

[0214] The product in well CI is confirmed as the cKIT interaction listed above (ORF3_4_54711719_54715167_54736749_54740853_FR). This data indicates a direct effect of imatinib on cKIT 3C chromosome conformation.

[0215] MMP1 interactions in BT142 cell line are shown below, which confirms the quality of the sample. This is a hydrolysis probe based assay.

[0216] TIFF0007579003000017.tif47170

[0217] Effect of GSK864 on treated cell lines MMP-1 3C quantification using non-fixed controls and samples treated with formaldehyde. Exemplary cell lines used in this application are: (a) DBTRG-05MG (glioblastoma) (b) HL-60 (acute myeloid leukemia) It is.

[0218] These cell lines were treated with the IDH1 inhibitor GSK864 for 24 and 48 hours. Binary differences are observed in cell line DBTRG and quantitative differences are observed in HL60 indicating a direct effect of the compound on MMP1 chromosome conformation (see FIG. 8).

[0219] TIFF0007579003000018.tif50170

[0220] The HL60 cell line was treated with the IDH1 inhibitor GSK864 for 24 and 48 hours. A binary quantitative difference is observed in the 3C MMP1 copy number in the cell line HL60 indicating a direct effect of the compound on MMP1 chromosome conformation (see FIG. 9).

[0221] TIFF0007579003000019.tif50170

[0222] summary These single-step assays using SYBR Green detection distinguish between normal blood and malignant material (see cell lines listed in the table above). qPCR 3C copy number may be significantly decreased in malignant cell lines when compared to normal material (e.g., cKIT and FLT3) or increased, for example, in CCL30 FGFR1 cell lines.

[0223] The drug imatinib (Glivec: Novartis PLC) is thought to act against the BCR-ABL protein. We show a novel direct effect of imatinib on a 3C conformational interaction identified in the gene cKIT. The data indicate a direct therapeutic effect of imatinib on the 3C conformation.

[0224] Furthermore, GSK864 (an inhibitor of IDHl mutations) shows a direct effect on 3C MMPl copy number at 1 μM in the cell lines DBTRG and HL60.

Claims

1. A method for providing an indication of prognosis of glioma or acute myeloid leukemia in a subject, the method comprising detecting the presence or absence, in a sample from said subject, of at least one epigenetic chromosomal interaction on chromosome 4 associated with the FIP1L1 and PDGFRA genes, said epigenetic chromosomal interaction being (i) a probe comprising: (f) 5'-TATGCTTGTGGGGACATCGACAAAAGCAATTATC-3' to detect the chromosomal interaction formed by position numbers 54231931-54236063 and 55143356-55145047 (k) 5'-TCAGCAAGGACCTCGAAAAGATAAAACA-3' for detecting the chromosomal interaction formed by position numbers 54278879-54279091 and 53379986-533880176 (l) 5'-ATTTATTCGAAAACCCTGGGACCC-3' to detect the chromosomal interaction formed by position numbers 53361094-53361416 and 54281778-54281990 or (ii) the following primer pair: (m) TTCCACGTGGCCTACCAG and CAGCTGCGAGGTTTTCTTTTT to detect the chromosomal interaction formed by position numbers 53379986-53380174 and 54294960-54295285 (n) TGGGAGTGGGTGGAGTGAGGAGA and ACGGACTGACATCTTTAGCTTCC for detecting chromosomal interactions formed by position numbers 53379986-53380318 and 54285685-54285944 (o) GCAGCTGCGAGGTTTTCTTT and GCCATGTGGCTTGGGCATAC to detect chromosomal interactions formed by position numbers 53379986-53380176 and 54278879-54279091 (p) AGTACTTCCTCTCCCCCTCCCA and GCAGCTGCGAGGTTTTCTTTTT to detect chromosomal interactions formed by position numbers 53379986-53380194 and 54281532-54281784 (q) CCTCTCCCACACAAACCTGCTA and ACATGGAGCACACATACAAGCTAC to detect chromosomal interactions formed by position numbers 53361094-53361416 and 54281778-54281990 (r) AAATGATGAGGCACGGGTGAA and CATGGAGCACACATACAAGCTAC to detect chromosomal interactions formed by position numbers 53369589-53369898 and 54281778-54282010 Either and detecting the presence or absence of said epigenetic chromosomal interaction by: (i) in vitro cross-linking chromosomal regions that together undergo chromosomal interactions to form a cross-linked nucleic acid; (ii) subjecting the bridged nucleic acid to enzymatic restriction digestion cleavage to form bridged cleaved nucleic acid ends; (iii) ligating the bridge-cleaved nucleic acid ends to form a ligated product; (iv) detecting the ligation product by the selected probe or primer pair; thereby determining the presence or absence of said epigenetic chromosomal interaction, wherein the presence of said epigenetic chromosomal interaction indicates that said glioma or acute myeloid leukemia is responsive to tyrosine kinase inhibitor therapy.

2. The method of claim 1, wherein a probe is used for detection, and a fluorophore is covalently attached to the 5' end of the probe.

3. The method according to claim 1 or 2, wherein a probe is used for detection, and a quencher is covalently bound to the 3' end of the probe.

4. 3. The method of claim 2, wherein the fluorophore is selected from HEX, Texas Red and FAM.

Citation Information

Patent Citations

  • Chromosome conformation capture-on-chip (4c) assay

    JP2009500031A

  • Ring chromosome conformation capture (4C)

    JP2010515449A